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1. SUMMARY
1 Summary
Programmed apoptotic cell death is critical not only for the development and the
life cycle of multi-cellular organisms, but also for maintaining the balance between
immunity and self-tolerance.
Several diseases like Systemic Lupus erythematosus, Autoimmune lymphoprolife-
rative syndrome, Rheumatoid arthritis, as well as Thyroiditis have been linked to
alterations of apoptosis.
For Dendritic Cells (DCs) it was shown that inhibition of caspases by the baculo-
viral p35, expressed under the control of a DC specific CD11c promoter, causes a
defect in DC apoptosis which leads to their accumulation, and results in autoim-
munity [1]. This and other studies interfering with DC death suggested that DC
apoptosis is an important regulator for maintaining immune self-tolerance [2, 3, 4].
However, a lot of the proteins investigated in the context of apoptosis in DCs are
not unique for DCs but show a broad expression throughout many different hae-
matopoietic cell types, or are not expressed naturally in DC (like p35).
Recent comparative promoter analyses published by our group revealed previously
unknown genes that share promoter organization with the promoter region of the
DC marker CD11c [5]. One of those genes encodes for the “Protein Phosphatase
with EF-Hands 2” (Ppef2); a rarely described phosphatase with three EF-hands
and an IQ motif. The expression of Ppef2 was DC-specific and downregulated ra-
pidly after activation with toll-like receptor (TLR) ligands.
Here we further characterized the expression of Ppef2 and generated mice deficient
for this phosphatase to investigate its role in the context of DC biology. We found
that Ppef2−/− DCs displayed increased apoptosis in vitro and in vivo. We also
showed that the reduced longevity of DCs caused by the loss of Ppef2 correspon-
ded to a decreased transient T cell activation in vivo.
In order to find the mechanism by which Ppef2 influences DC apoptosis, we perfor-
med an mRNA sequencing assay and identified tripartite motif protein 2 (Trim2)
as differently expressed in Ppef2−/− CD8+ cDCs. Trim2 drives apoptosis by mo-
dulating the abundance of BCL-2–interacting mediator of cell death (Bim), which
was also increased in Ppef2−/− mice.
In conclusion, we showed that Ppef2, specifically expressed by CD8+ DCs and
downregulated after maturation, is a driver of DC apoptosis through Trim2 and
Bim.
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2. ZUSAMMENFASSUNG
2 Zusammenfassung
Programmierter Zelltod (Apoptose) ist nicht nur für die Entwicklung mehrzelliger
Organismen, sondern auch für die Aufrechterhaltung des Gleichgewichts zwischen
der Ausbildung einer immunologischen Antwort und der Toleranz gegenüber Selbst
von immenser Bedeutung.
Krankheiten wie Systemischer Lupus erythematodes, rheumatoide Arthritis, das
autoimmun-lymphoproliferative Syndrom und Thyreoiditis wurden mit der Ver-
änderung apoptotischer Prozesse in Verbindung gebracht. Dass Apoptose auch
im Kontext von Dendritschen Zellen (DCs) eine maßgebliche Rolle spielt wurde
unter anderem durch die Zell-spezifische Inhibition von Caspasen gezeigt. Die so
herbeigeführte Akkumulation von DCs führte schlussendlich zur Ausbildung von
Autoimmunität [1]. Diese und andere Studien die sich mit der Langlebigkeit von
DCs befassten legten den Schluss nahe, dass die Apoptose von DCs ein wichtiger
Regulator für die Aufrechterhaltung der immunologischen Toleranz ist [2, 3, 4].
Viele der in diesem Zusammenhang untersuchten Proteine sind jedoch nicht spezi-
fisch für Dendritische Zellen, sondern zeigen vielmehr ein breites Auftreten in den
verschiedensten Zelltypen.
Durch kürzlich veröffentlichten Analysen des Promotorbereichs von DC spezifi-
schen Genen fand unsere Gruppe weitere bislang weitgehend unbekannte Gene,
die dieselbe Promotorstruktur wie der weitläufig verwendete DC Marker CD11c
aufwiesen [5]. Eines dieser Gene kodiert für die Phosphatase Ppef2 (Protein Phos-
phatase EF-Hand 2 ). Erste Analysen der Expression von Ppef2 zeigten ein DC
spezifisches Expressionsmuster, welches auf Aktivierung von DCs durch TLR Li-
ganden mit der Herunterregulation der Ppef2 Expression reagierte.
In der vorliegenden Arbeit charakterisierten wir die Expression von Ppef2 detail-
liert und generierten Mäuse, die diese Phosphatase nicht mehr exprimieren, um so
ihre Rolle im Kontext von Dendritschen Zellen weiter zu erarbeiten.
Wir konnten so in vitro und in vivo zeigen, dass Ppef2 defiziente DCs vermehrt
apoptotisch sind. Weiterhin konnten wir zeigen, dass die so verkürzte Lebenszeit
von CD8+ DCs zu einer verminderten T Zell Proliferation führte. Durch Sequen-
zierungsanalysen von Ppef2 defizienten DCs war es uns schlussendlich möglich
Trim2 als differentiell exprimiert in CD8+ DCs identifizieren. Mechanistisch führt
Trim2 wiederum durch eine Erhöhung von Bim, welche wir ebenso in Ppef2 defi-
zienten Tieren nachweisen konnten, zur verstärkten Apoptose von CD8+ DCs.
Zusammenfassend weisen unsere Daten darauf hin, dass Ppef2 ein Regulator für
das Überleben von DCs ist.
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3. INTRODUCTION
3 Introduction
3.1 The immune system of higher vertebrates
The human organism is facing a broad range of potential pathogens. However, only
in rare cases these infections lead to the outbreak of a disease. Humans therefore
developed a variety of defense mechanisms during evolution as a reaction to new,
emerging pathogens.
The immune system of higher vertebrates is separated into two branches, the evo-
lutionary older innate immune system, and the adaptive immune system. When
a potentially harmful pathogen breaks through the naturally existing barriers li-
ke skin or the gastrointestinal tract, the innate immune system orchestrates the
first protective response against the pathogen. Together with antibacterial pep-
tides like α-defensins, the complement system, and cellular components like NK
cells and granulocytes, the innate immune system also has an extensive variety of
defense mechanisms that act mostly by recognizing foreign molecular structures
or patterns with only a limited repertoire of receptors for the respective antigens
(reviewed in [6, 7]).
The other arm of the immune system is the so called adaptive immune system,
which consists of B cells and T cells. Adaptive immunity is activated by the innate
immune system and therefore acts chronologically later than innate immunity with
high affinity and specificity. The wide array of specific antigen receptors of B and T
cells are generated by combining a limited number of gene segments in a process
called V(D)J-recombination. This somatic recombination occurs semi-randomly
and generates a very high variety of antigen receptors, not only against unknown
structures of all different kind, but also against self antigens. As a consequence,
the developmental process of these antigen receptors has to be tightly controlled
and there is a need for mechanisms by which potential self-reactive cells have to
be controlled or deleted. Another hallmark of the adaptive immune system is the
acquirement of an immunological memory. In case of a second infection with the
same pathogen this leads to a faster and better reaction, with antibodies of higher
affinity.
In the end, innate immunity has a smaller antigen receptor repertoire than the
adaptive immune system but acts faster and is also necessary to activate the latter.
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3.2 Dendritic Cells
DCs were first described in the 1970s by Ralph Steinman and Zanvil Cohn [8, 9].
Their morphology was described as a “variety of cell shapes ranging from bipolar
elongate cells to elaborate, stellate or dendritic ones” [8] which led to their name
as Dendritic cells. Over the past forty years and a Nobel Prize later it became
evident that DCs are unique antigen presenting cells (APCs) that link innate
and adaptive immunity [10]. Their location in lymphoid and non-lymphoid organs
together with the expression of several pathogen recognition receptors (PRRs)
leads to an early recognition of pathogens. This results in the maturation of DCs,
which is characterized by upregulation of major histocompatibility complex class
II (MHCII), production of costimulatory molecules, expression and secretion of
cytokines, as well as enhanced migratory capacities. All of these characteristics
are described in more detail in the following chapters.
3.2.1 Development and heterogenity of DCs in vivo
Comprehensive studies of DC biology led to the identification of distinct DC sub-
types and their respective biogeneses. Several studies tried to clarify the develop-
mental origin of the different DC subtypes, facing the problem that DC subsets
of different organs can have different origins. Most insight in classical DC (cDC)
development was gained through animal models that were deficient in certain
transcription factors, cytokines, cytokine receptors, or by transferring specific pre-
cursors into irradiated mice.
By now the cDC lineage is considered as a distinct hematopoietic branch. One of
the early progenitor transfer experiments led to the conclusion that common mye-
loid progenitors (CMPs) can give rise to CD8+ and CD8− DCs [11]. The authors
also found that common lymphoid progenitors (CLPs) can give rise to CD8+ and
CD8− DCs in the spleen and the thymus but only if transferred in higher numbers.
The fact that CMPs are 10 times more numerous than CLPs suggested that, on
a per cell basis, CMPs are the major producers of splenic and lymph node DCs,
whereas CLPs are more potent in producing thymic DCs [12]. Other studies fo-
cusing on Lin−c-kit+Thy-1lowCD4low intrathymic lymphoid-restricted precursors
showed that also those cells can develop into thymic CD8+ DCs in an irradia-
ted thymus [13], distinguishing thymic CD8+ DCs development from CD8+ DCs
of other organs. Commitment to the mononuclear phagocyte lineage takes place
when CMPs further differentiate into granulocyte-macrophage precursors (GMPs)
or macrophage/DC precursors (MDPs) [14]. MDPs were shown to be able to dif-
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ferentiate into spleen macrophages, lymphoid tissue resident classical Dendritic
Cells (cDCs), non-lymphoid tissue-resident cDCs, and some plasmacytoid Den-
dritic Cells (pDCs), but not granulocytes [14]. Macrophage potential is lost when
MDPs differentiate into common DC precursors (CDPs), which were initially defi-
ned as Lin−c-kitintFlt3+Csf-1R+ and shown to be able to generate cDCs and pDCs
in cultures supplemented with FMS-like tyrosin kinase 3 ligand (Flt3L) [15]. In
vivo transferred CDPs produced spleen and LN cDCs and pDCs but showed no
potential to develop into macrophages [15]. The last differentiation step of DC
progenitors takes place after the CDP stage, when CD11c+MHCII− proliferative
precursors (pre-cDC) are able to differentiate into CD8+ and CD11b+ cDCs but
not into pDCs. Pre-DCs were shown to migrate from the bone marrow along high
endothelial venules to home to lymphoid and non-lymphoid organs [16].
Monocytes were also believed to be precursors of cDCs but studies showed that mo-
nocytes generate only very few cDCs when transferred in steady-state recipient mi-
ce. However, in mice with an ongoing granulocyte-macrophage colony-stimulating
factor (GM-CSF) dependent inflammation, monocytes were able to give rise to
CD11cintCD11bhiMac-3+ DCs in various organs, including the spleen [17]. This
finding reflected the ability of monocyte to convert into DCs in vitro when cultured
in GM-CSF containing medium. Later studies investigating the role of the Notch2
receptor revealed that the blockade of Notch signaling in DCs affected a populati-
on within the CD11b+ DCs compartment that was distinguished by the expression
of the endothelial cell-selective adhesion molecule (ESAM). ESAMhiCD11b+ DCs
were ablated after blocking Notch2 signaling, whereas ESAMlo DCs were unaffec-
ted. Closer investigation of the ESAMlo cells revealed a more monocyte-specific
expression profile suggesting that these cells arise from monocytes in the steady
state [18].
Regulation of the developmental pathways mentioned above is affected extrinsi-
cally by hematopoietic cytokines and intrinsically by transcription factors. With
regard to control by cytokines, it was shown that FMS-like tyrosin kinase 3 (Flt3),
which is expressed by CLPs, MLPs, and steady state DCs in spleen, thymus and
epidermis [19], is necessary for DC lineage commitment, as precursors that lack
Flt3 expression also lose the potential to differentiate into DC [19]. Another cy-
tokine used to generate cDC from monocytes and hematopoietic progenitors in
vitro is GM-CSF. Surprisingly, mice lacking GM-CSF, or its corresponding re-
ceptor, showed normal development of spleen and LN cDCs [20]. However, it was
shown that GM-CSF is necessary for the survival and homeostasis of non-lymphoid
tissue-resident CD103+ and CD11b+ DCs [21].
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Transcriptional control of DC development involves, amongst others, IFN regula-
tory factors (IRFs), basic leucine zipper transcription factor ATF-like 3 (Batf3),
and PU.1. IRFs show a subset-specific expression and regulation profile. IRF4, for
example, is expressed by CD4+ DCs, while IRF8 is expressed in CD8+ DCs. Con-
sequently, lack of IRF4 leads to loss of CD4+ DCs, whereas loss of IRF8 results in
failure to generate spleen-resident CD8+ DCs and pDCs [22]. In the case of Batf3
the expression pattern doesn’t match the effect observed in knockout (KO) strains.
Batf3 is expressed in all cDCs, but mice lacking Batf3 showed a background-
specific impact only on splenic CD8+ DCs and CD103+ DCs [23].
3.2.2 DC subsets and their phenotype
DCs are a heterogeneous population of cells. Thus, it is important to distinguish
between the different DC subtypes in regard to their development and functional
specializations. As already discussed in section 3.2.1, with regard to their origin,
we can differentiate between cDCs and pDCs. Conventional DCs include both mi-
gratory and lymphoid-resident subsets.
pDCs were first described by Lennert and Remmele in 1958 as plasma cell-like
cells that were missing B cell and plasma cell markers and were characterized by
the ability to produce large amounts of type I interferons in response to viruses
[24]. They express low levels of MHCII and costimulatory molecules, as well as
intermediate levels of CD11c in the steady state. As one of the hallmarks of pDCs
is the reaction to viral infections, they also express a range of pattern-recognition
receptors that include TLR 7 and 9, sensing the presence of viral DNA and RNA
[25]. Based on the expression of pDC specific markers like mPDCA-1 [26] and
others, pDCs were found in lymphoid organs and also in liver, lung, and skin
[27, 28].
The other branch of DCs are conventional DCs. cDCs include all DCs except pD-
Cs. They are a small population of hematopoietic origin (see section 3.2.1) found
in lymphoid and non-lymphoid tissues. As major APCs, distributed through sever-
al different tissues, DCs have an enhanced capacity to capture and subsequently
process and present environmental- and cell-associated antigens to T cells. The-
se key features of DC biology will further be discussed in section 3.2.3. Despite
their broad distribution, DCs from different tissues can all be defined by a set of
common markers, such as the integrin CD11c, and MHCII. They also lack surface
expression of T cell, B cell, NK cell, granulocyte, and erythrocyte lineage markers.
CD11c as it is the marker broadly used for the definition of cDCs, is also used
in many mouse models to control the DC-specific expression of the Cre transgene
6
3.2 Dendritic Cells
[29]. However, CD11c expression is also found on several macrophage populati-
ons, especially in the lung and intestine, and therefore other more cDC specific
markers have been recently investigated. One of these is the transcription fac-
tor Zbtb46 [30, 31]. Diphtheria toxin receptor or green fluorescent protein (GFP)
reporter-based studies could distinguish cDCs from macrophages. Interestingly,
the Zbtb46 GFP reporter mice showed some heterogeneity of the GFP signal in
the CD103− CD11b+ cDC subset of the lung, where only 42% of cells were posi-
tive for GFP [31]. TNF-α/iNOS-producing Dendritic Cells (TIP-DCs) displayed
little to no tissue expression of Zbtb46, which makes them less likely to be DCs
and instead potentially have macrophage identity. For this reason, these cells will
not be further discussed in detail in this and the following chapters. Epidermal
Langerhans cells (LCs) on the other hand did also show expression of Zbtb46 [32].
However, since LCs differ not only in their ontogeny, yolk sac-derived instead of
bone marrow-derived, but also in their homeostasis from cDCs they will not be
discussed in greater detail in the following chapters which will focus more on clas-
sical DCs.
cDCs can be further subdivided into CD8+/CD103+ and CD11b+ subsets [33, 34,
35]. Both subsets are discussed below.
3.2.2.1 CD8+/CD103+ DCs
The first flow cytometric analyses of splenic and thymic DCs revealed a heteroge-
neity concerning the surface expression of CD8 [36, 37]. Therefore this cDC subset
was the first to be described in more detail. CD8+ DCs account to 20–40% of
spleen, LN, and thymus cDCs. However, thymic cDCs differ in their expression
of CD8 from spleen and LN cDCs in regard to the expression of the α and β
chains. Thymic cDCs express both the CD8 α and β chains, whereas splenic cDCs
exclusively express the α chain [37].
In non-lymphoid tissues CD8 expression is not found on DCs, but instead the
equivalent subset to CD8+ DCs are characterized by surface expression of CD103
[38, 39]. The transcriptomes of lymphoid tissue CD8+ and non-lymphoid tissue
CD103+ DCs are closely related and are clearly distinguishable from CD11b+
DCs [33]. Furthermore, both CD8+ and CD103+ DCs express the cytokine recep-
tor Xcr1 [40, 41] which makes it a unifying marker for these DC subtypes. The
CD8+/CD103+ DC-specific expression of several lectin receptors like DEC205 [42]
and Clec9A [43] also makes these surface proteins useful markers. Functionally,
CD8+ and CD103+ DCs are characterized by the production of high amounts of
IL-12p70 after stimulation with TLR ligands [44]. The production of IL-12 by
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CD8+ cDCs differs from that by macrophages because of the requirement of c-Rel
in the former [45].
3.2.2.2 CD11b+ DCs
The CD11b+ DC compartment is characterized by a higher heterogeneity as com-
pared to CD8+/CD103+ DCs. They express CD11b and DCIR2 (also called 33D1)
[42], and lack the expression of CD8+ and CD103+. Markers for further subdivision
are CD4 and ESAM [18]. High expression of ESAM correlates with an increased ex-
pression of CD4, CD11c, and Flt3, whereas low expression of ESAM corresponds
to a monocyte-like expression signature, although they do not seem to derive
from monocytes [18]. However, this subdivision according to ESAM expression
still does not result in a homogeneous population, as shown by parallel single-cell
transcriptome analysis [46]. Probably the most functionally relevant difference
between CD11b+ and CD8+/CD103+ cDCs is that the former are not capable of
cross-presenting antigens (described in section 3.2.3) [42], but are superior in the
induction of CD4 T cell responses.
3.2.3 DCs in immunity and tolerance
A hallmark of DCs is their high functional plasticity, which allows them to either
initiate immunity or tolerance. In steady state, DCs are located in the subcapsular
sinus of the LN, or the T cell zones and the marginal zone of the spleen. Both po-
sitions enable DCs to sense circulating pathogens: in the subcapsular sinus as the
entry site of afferent lymphatic vessels, or in the spleen by filtering blood antigens
[47, 48], with new publications showing also an important role of macrophages
in filtering blood antigens in the spleen [49]. These DCs can be distinguished in-
to two developmental stages (mature and immature), which are defined by their
expression of costimulatory molecules [50, 51], and their phagocytic activity [52].
Most spleen DCs in steady state show low levels of costimulatory molecules and,
in contrast to tissue-migratory cDCs which are in a more mature state, can still
present newly encountered antigens [53, 52]. Furthermore, other features, except
for their superior location for the induction of immunity or tolerance, are their
exceptional antigen processing and presentation machinery, their remarkable ca-
pability of migrating to T cell zones of LNs, and finally their notable competence
in priming naive T cells [47, 48, 54].
The transcriptome of CD8+ DCs suggests that they are better equipped to pre-
sent antigens via MHCI than CD11b+ DCs [42]. Indeed, ex vivo studies revea-
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led the superior ability of CD8+ and CD103+ cDCs to present microbial [55]
and cell-associated antigens [23, 56, 57, 58] to CD8+ T cells, when compared to
CD11b+ DCs. CD11b+ DCs on the other hand show higher expression of genes
encoding for proteins involved in the MHCII processing and presenting machinery
[42]. Another feature of CD8+ and CD103+ DCs is their ability to load exoge-
nous antigens onto MHCI and presenting them to CD8+ T cells, a process called
cross-presentation [42, 57, 59]. Although cross-presentation seemed to be limited
to CD8+ and CD103+ DCs, it was shown that also CD11b+ DCs can be induced
to cross-present OVA/anti-OVA immune complexes to CD8+ T cells in an Fcγ re-
ceptor dependent fashion [60]. For viral infection models the question still persists
whether CD11b+ DCs are able to present viral antigens to CD8+ T cells. For ex-
ample, in the case of influenza infection, it was shown that the CD103− CD11bhigh
DCs controlled antigen presentation at the peak of infection [61]. However, it is
questionable whether the MHCI dependent presentation in such cases is the result
of cross-presentation of infected cell-associated antigens, or direct presentation.
Mechanistically, cross-presentation is dependent on endocytosis and a phagosome-
to-cytosol transport system. This requires the endocytic pathway to have a low
lysosomal proteolytic activity [62, 63], and the intracellular transport system has
to ensure antigen trafficking from the phagosome to the cytosol and subsequently
the loading onto MHCI molecules [64].
Tolerance can be subdivided in central tolerance and peripheral tolerance, based
on the induction site. In primary lymphoid organs, like the thymus and the bone
marrow, T cells or B cells, respectively, are tested for autoreactivity after they
rearrange their corresponding receptor. In the thymus, T cells that react stron-
gly with MHC-self peptide complexes either have to be converted in regulatory T
cells (Tregs), or undergo apoptosis in order to be removed as potentially harmful
autoreactive T cells. Central tolerance induction in the thymus is mediated by
endogenous CD8+ DCs or circulating CD11b+ DCs from the blood (reviewed in
[65, 66]). Although this mechanism is very efficient in ridding the organism of po-
tentially harmful autoreactive T cells, some still leave the thymus and are found in
the periphery. In this case, CD8+ cDCs of the periphery take up self antigens, e.g.
in form of dying cells, and present them by cross-presentation to antigen-specific
CD8+ T cells [47, 67, 68], a process termed cross-tolerance induction. The same
was shown for migratory CD103+ DCs in the lamina propria, where DCs were
able to induce peripheral Tregs in vivo. The conversion of naive T cells into Treg
cells is dependent on TGF-β and retinioc acid. CD103+ DCs express high levels of
aldehyde dehydrogenase (ALDH), which converts dietary vitamin A into retinoic
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acid [69, 70], as a basis for Treg cell conversion.
3.2.4 DC homeostasis
Since DCs are the major APCs and are able to initiate either immunity or tole-
rance, multiple mechanisms control maturation and life span of DCs to guarantee
a balanced immunological state.
Early experiments addressing DC turnover were carried out by bromodeoxyuridine
(BrdU) labeling of DCs or their respective precursors in vivo. BrdU, a chemically
modified thymidine analog, enters dividing cells and is incorporated into the DNA,
where it can be stained with specific antibodies and analyzed by flow cytometry.
It was shown that CD8+ DCs have a turnover rate of 1.5 days, whereas CD8−
DCs have a slower turnover of 3 days in the spleen of mice [52]. Skin resident
Langerhans cells (LCs) are an exception among DCs, as they showed a remar-
kable 3- to 4-fold slower BrdU labeling rate [71]. In contrast with the long-held
belief that tissue DCs are terminally differentiated non-dividing cells, short time
BrdU labeling revealed that about 5% of lymphoid-resident DCs are undergoing
cell division at any given time [72]. Furthermore, parabiosis experiments where
two CD45 allotypic mice were surgically joined in order to obtain a shared blood
circulation revealed that the majority of DCs were not exchanged between hosts
after 6 weeks (10–30% being parabiotic partner derived), whereas T and B cells
reached equilibrium distribution [72]. This argued in favor of a local renewal ca-
pacity for cDCs.
However, this has to be considered carefully since cells and proteins with short
half-lives in circulation never reach equilibrium in parabiotic mice and DC precur-
sors are known to have a short half-life. Additionally, chimerism in the blood of
parabiotic mice reflected the DC chimerism in lymphoid organs [73]. Ten to four-
teen days following separation of parabiotic mice, DCs of spleen and lymph nodes
were completely replaced by endogenous bone marrow-derived cells [73]. These
findings rather argue for a half-life of 5 to 7 days than the half-lives estimated by
short time BrdU labeling. However, in steady state homeostasis, the maintenance
of DC populations relies on constant replenishment by blood-borne cells [73, 74]
(with a rate of precursor input of nearly 4,300 cells per hour [73]), as well as in
situ cell division.
The first evidences of factors regulating DC division and homeostasis were found
in 1996, when Maraskovsky and colleagues observed that administration of the
ligand for the receptor tyrosin kinase Flt3 in vivo led to an increase in the number
of peripheral DCs [75, 76]. At the same time, inhibition of Flt3-mediated signals
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resulted in a reduction of peripheral DCs [77, 78]. Flt3 seemed to be an essential
regulator of homeostatic DC division, since mixed bone marrow chimeras of Flt3-
deficient and -sufficient mice showed fewer Flt3−/− DCs and pDCs. Finally, BrdU
experiments revealed the necessity of Flt3 for DC in situ proliferation [74].
Mice deficient in the lymphotoxin (LT)-β receptor (LTβR), a family member of
TNF receptors, or its membrane-associated ligand, LTα1β2, have reduced num-
bers of DCs in the spleen [79], but at the same time show an increase in DCs
in non-lymphoid tissues; this fact, and the known role of LTα1β2 in promoting
chemokine and adhesion molecule expression, led researchers to hypothesize a se-
condary recruitment or retention effect [79]. Others however, hypothesized that
LTα1β2 might instead act as a growth or survival factor. Indeed, studies of BM
chimeras and BrdU incorporation experiments showed such an effect on DCs of
spleen and lymph nodes. However, this effect appears to be limited to CD11b+
DCs as CD8+ DCs were unaffected by the loss of LTβR [72, 80].
Another player in DC homeostasis is the TNF family member TRANCE (tumor
necrosis factor [TNF]–related activation-induced cytokine). Unlike Flt3 and LTβ,
TRANCE does not have much influence on steady state DCs, since TRANCE-
deficient mice do not show a deficiency of DCs [81]. However, the TRANCE re-
ceptor is highly expressed in DCs and studies on TRANCE-treated, mature bone
marrow-derived DCs showed enhanced survival through inhibition of apoptosis,
which was mediated by upregulation of Bcl-xL [82]. The increased survival of
TRANCE-treated DCs also resulted in a stronger induction of T cell responses
after DC vaccination [2], suggesting that the abundance and longevity of mature
DCs influences the strength of T cell immunity in vivo.
GM-CSF, a cytokine used for the in vitro generation of DCs [83], is a hematopoie-
tic growth factor that controls the differentiation of the myeloid lineage [84]. In
consideration of the usage of GM-CSF for DC in vitro studies, it came as a surprise
that mice lacking expression of this cytokine or its receptor showed only a minor
impairment in the development of spleen and LN cDCs [20]. More recent studies
showed that GM-CSF plays a role in the survival of non-lymphoid tissue cDCs,
which were decreased in the intestine, lung, and dermis of GM-CSF-deficient mi-
ce. Furthermore, remaining tissue cDCs in these mice showed a more proapoptotic
phenotype [21].
The importance of DC homeostasis, in situ proliferation, and DC death beco-
mes obvious when the system is disturbed. After microbial stimulation, in vivo
BrdU labeling revealed increased DC turnover [52, 85]. Inhibition of caspases by
expression of the baculoviral p35 under the control of a CD11c promoter leads to
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a defect in DC apoptosis followed by their accumulation and autoimmunity as a
result of chronic lymphocyte activation [1]. The same group showed that systemic
autoimmunity observed in Bim-deficient mice is not exclusively explained by a
defect in negative selection of T cells in the thymus, but also by the ability of
Bim-deficient DCs to actively induce autoimmunity [86]. Similar to these findings,
systemic autoimmunity detected in mice lacking the receptor on all cells was tra-
ced back to DCs, which seemed to be sufficient for the induction of autoimmunity
and the production of autoantibodies when loss of the Fas receptor was DC spe-
cific [87]. Another regulator of DC survival is Bcl-2, which, when constitutively
expressed in DCs, enhances survival [3]. Prolonging the lifespan of DCs by a con-
stitutive, “functionally optimized”, Akt allele enhanced immunogenicity, exempli
gratia (e.g.) against tumors [88].
12
3.3 Ppef2
3.3 Ppef2
The gene family of mammalian serine-threonine phosphatases with EF-hand pro-
tein motifs was first described in 1997, and named Ppef, short for Protein Phos-
phatase with EF calcium-binding domain [89]. In the original study, the phospha-
tase investigated showed high homology with Drosophila retinal degeneration C
(rdgC), which was known to be important to prevent retinal degeneration in Dro-
sophila [90]. Amino acid (AA) sequence comparison with rdgC showed homology
with other members of the protein phosphatase family. The identified catalytic
phosphatase domain ranges in case of murine Ppef2 from AA 128–544 (Fig. 3.1).
The sequence of human Ppef showed two EF-hand motifs, which consist of a helix-
loop-helix domain found in a large family of calcium-binding proteins [89]. Ppef2,
which was described afterwards together with Ppef1 [91], contains three EF-hand
domains with two potential Ca2+ binding sites (Fig. 3.1).
Because of the expression pattern, with highest levels in the retina (Fig. 3.2 A),
Ppef2 was long believed to play a role in sensory neurons. Surprisingly, mice de-
ficient for Ppef2 did not show any signs of a defect of rod function or alterations
of retina integrity. Even a Ppef1 and Ppef2 double knockout appeared to have
normal rhodopsin phosphorylation and dephosphorylation, as well as no signs of
retinal degeneration [92]. The study of protein organization and functional do-
mains showed that Ppef2 of Caenorhabditis elegans (rdgC) is able to bind to Ca2+
[93], while the human Ppef2 is able to bind to calmodulin [94]. However, binding
of calmodulin to the closely related human recombinant Ppef1 did not influence
its phosphatase activity [95]. Furthermore, different microarray studies suggest a
role of Ppef2 in stress-protective responses and a possibly positive participation
in cell survival, growth, proliferation and oncogenesis (reviewed in [96]).
1 757128 544- Catalytic domain -IQ EF-hand
Ca2+ binding
(potential)
Metal binding (Iron & Manganese)
(Predicted by similarity)
Figure 3.1: Schematic representation of the Ppef2 protein structure. Displayed
is a schematic representation of the Ppef2 protein as provided by uniprot.org. The most
N-terminal motif is an IQ motif starting at amino acid (AA) 21. The catalytic phospha-
tase domain ranges from AA 128 to 544 and is shown in purple. Three EF-hand domains
are located between AA 544 and 757 with two potential Ca2+-binding domains within
the EF-hands.
The first and so far only functional report of Ppef2 in mammalian cells showed
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evidence of a strong interaction of human Ppef2 with the pro-apoptotic MAP
kinase kinase kinase Apoptosis signal-regulating kinase 1 (Ask1) [97], after the
same group performed large scale expression analyses and found that expression
of Ppef phosphatases was influenced by apoptosis-inducing or apoptosis-inhibiting
treatments and had a tendency to be elevated in apoptosis-resistant cells [96]. The
interaction of Ppef2 with Ask1 led to dephosphorylation of Ask1 at the threonine
residue 838 in COS-7 or HEK 293 A cells after treatment with H2O2. Phosphoryla-
tion at this residue was previously shown to be important for Ask1 activity and
therefore serves as indicator of Ask1 activity [98]. Ppef2 seemed to be more potent
in dephosphorylating Ask1 than the already known inhibitor serine/threonine pro-
tein phosphatase 5 (PP5) after oxidative stress. Finally, in a system where Ask1
and Ppef2 were either individually or co-expressed in HEK 293 A or COS-7 cells,
suppression of Ask1 by Ppef2 led to an increase in caspase-3 activation. However,
this was not seen when Ppef2 was expressed without Ask1, in which case the basal
level of caspase-3 activity did not change [97].
Genetic and molecular characterization of the promoter region of DC specific ge-
nes, particularly CD11c and DC-STAMP, led to the identification of an evolutio-
nary conserved promoter framework consisting of 4 transcription factor binding
sites [5]. This motif spanning about 250 base pairs, which was sufficient to drive
DC specific gene expression, was further used for a proactive promoter database
search, leading to the identification of two genes, Pftk1 and Ppef2, that shared
the previously found promoter motif and are preferentially expressed in DCs, ac-
cording to microarray data (Fig. 3.2). Quantitative PCR (qPCR) of sorted spleen
DCs and bone marrow-derived dendritic cell (BMDCs) confirmed the expression
in DCs. Interestingly, expression of Ppef2 was higher in CD8+ DCs compared to
CD8− DCs, and stimulation of BMDCs with lipopolysaccharide (LPS) led to a
reduction of Ppef2 expression [5]. In accordance with this finding, the data sets of
the Immgen Consortium [99] and BioGPS [100], generated from high throughput
data, show the same expression pattern for Ppef2 (Fig. 3.2). BioGPS (Fig. 3.2 A)
focuses on the different organs and offers a broad overview of the distribution of
expression, while the Immgen Consortium datasets are restricted to immunologi-
cally relevant cell types (Fig. 3.2 B & C). Across the different organs, expression
of Ppef2 is highest in the eye, or more precisely in the Retina, the retinal pigment
epithelium, and to a lesser extent the iris (Fig. 3.2 A). Notably, lymphoid CD8+
DCs (Fig. 3.2 A, shown in red) also show measurable expression of Ppef2. Focu-
sing on immunologically relevant cell types, like B cell and their precursors, DCs,
Macrophages, Monocytes, NK cells, Neutrophils and T cells of different organs
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(Fig. 3.2 B), Ppef2 expression is highest in CD8+ DCs of the spleen and thymus
(Fig. 3.2 B and C, red), though a similar expression is found also in CD8− DCs
of thymus (Fig. 3.2 B and C, blue). Blood monocytes (Fig. 3.2 B, yellow) are the
only other cells that show expression above background. Taking a closer look at
the different DC subtypes (Fig. 3.2 C), Ppef2 expression seems to be limited to
CD8+ DCs (Fig. 3.2 C, red) across several organs, and CD8− DCs (Fig. 3.2 B
and C, blue) of the thymus. The closely related CD103+ DCs (Fig. 3.2 C, green)
of liver, lung, lung draining lymph node, and small intestine also show expression
above background.
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Figure 3.2: Ppef2 expression profile. Expression data of Ppef2 was provided by
biogps.prg [100] (A) and the Immgen Consortium [99] (B & C). sLN, skin draining
lymph node; mLN, mesenteric lymph node; LuLN, lung draining lymph node.
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To study the roles of Ppef2 in vivo we generated Ppef2−/− mice. Embryonic stem
cells targeting Ppef2 with the so called “knockout-first” approach were therefor
purchased at the European Conditional Mouse Mutagenesis Program (EUCOMM)
and blastocyst microinjection was performed.
Differently from the traditional conditional approach, where an exon is flanked by
loxP sites and deleted after exposure to the Cre recombinase, the “knockout-first”
constructs act as gene trap by inserting an additional splice acceptor site after
an exon, which is followed by a polyadenylation site [101]. The major difference
between the Cre-lox system and gene traps is the possibility to delete a gene only
in certain cell types. This can be achieved by using a cell specific promoter for the
expression of the Cre recombinase, whereas gene traps act on all cell types. The
knockout-first construct in the locus of Ppef2 is shown in figure 3.3, together with
the possible breeding schemes to generate conditional Ppef2 knockout mice.
The so called targeted mutation 1a (tm1a) allele contains an IRES:lacZ trapping
cassette with a splice acceptor from engrailed-2 (EN2SA) after exon 4 (Fig. 3.3,
yellow boxes), as well as the highly effective SV40 polyadenylation signal down-
stream of a β-Galactosidase (lacZ) reporter, leading, in homozygous mice, to a
null allele with lacZ as reporter for promoter activity. This trapping cassette, to-
gether with a loxP site and a neomycin (neo) resistance, driven by an autonomous
promoter (hBactP), is flanked by Frt sites. Additional loxP sites are flanking exon
5. Crossing of mice containing the tm1a allele with mice expressing the Cre recom-
binase leads to loss of exon 5 and/or the neomycin selection cassette (tm1b). This
construct, leading to Ppef2 deficiency, still functions as lacZ reporter for promoter
activity.
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En2SA IRES lacZ pA hBactP neo pA
FRT FRTloxP loxP loxP1 4 5 6 16
En2SA IRES lacZ pA
FRT loxP1 4 6 16FRT loxP loxP1 4 5 6 16
FRT loxP1 4 6 16
Cre
CreFlp
tm1a
tm1btm1c
tm1d
Figure 3.3: The knockout-first construct and its conversion. The knockout-first
construct inserted within the Ppef2 locus consists of a gene trap cassette containing
an EN2 splice acceptor (EN2SA), fused with a Internal Ribosomal Entry Site (IRES),
followed by the gene coding for beta-galactosidase (lacZ), and a polyadenylation (pA)
signal. The selection cassette, consisting of a neomycin (neo) resistance driven by an
autonomous protomoter (hBactP), follows the gene trap cassette, and together they are
flanked by FRT sites. Additional loxP sites are found between the two cassettes, flanking
exon 5. Exons are depicted as yellow boxes and possible splicing is indicated by dashed
lines. The figure was modified from Skarnes et al. [102].
Exposure of the tm1a allele to a source of (ubiquitously expressed) Flp recom-
binase deletes the trapping cassette and restores normal gene activity, leaving a
“conditional-ready” allele with a floxed exon 5 (tm1c). Subsequent crossing to a
mouse line expressing the Cre recombinase under organ or cell type specific pro-
moter control leads to a loss of exon 5 resulting in frameshift and null mutation
(tm1d).
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DCs are professional antigen presenting cells that shape adaptive immune respon-
ses. The process of antigen capturing, processing, presenting to T cells, and finally
priming a T cell response is tightly controlled. DCs are replenished constantly
from a pool of hematopoietic stem cells and have a relatively short half-life. Con-
sistently, it was shown that control of DC survival, turnover, and longevity also
serves as a regulator of the priming of adaptive immune responses.
Ppef2, a phosphatase with EF-hands, was recently shown by our group to be ex-
pressed in a DC specific manner and to be downregulated after maturation of
DCs. The biological function of Ppef2 in DCs is not known albeit its DC specific
expression.
The goal of this study was to further characterize the DC specific expression of
Ppef2 in various cell types and organs, as well as the analysis of the role of this
phosphatase in the context of DC biology.
To this end, we generated a mouse model that allowed us to track the promo-
ter activity of Ppef2 and to investigate the influence of Ppef2 deficiency on DC
longevity, survival, turnover, as well as the ability to transiently activate T cells.
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4.1 Ppef2 expression profile analysis
Very little is known about Ppef2 in the context of DCs. Early studies showed ex-
pression in the CD8+ DC subset [5]. Therefore we performed qPCR analyses on
sorted splenic DC subsets to characterize the expression of Ppef2 in more detail
(Fig. 4.1 A). We also FACS-sorted classical blood monocytes, due to their expres-
sion profile shown by the Immgen database (Fig. 3.2 B). In accordance with the
Immgen data (Fig. 3.2), we found the highest expression in CD8+ DCs. CD11b+
ESAMlo DCs, together with monocytes of the blood, expressed Ppef2 to a smaller
extent, close to background signal. pDCs, T cells, and B cells on the other hand
did not show expression of Ppef2.
To test the abundance of Ppef2 not only on mRNA, but also on a protein level,
we took advantage of the knockout-first construct described in chapter 3.4. Direct
measurement of protein levels, e.g. by western blot, were not possible due to lack
of a functional antibody against Ppef2. In the knockout-first system, expression of
Ppef2 is directly coupled to the expression of β-galactosidase (lacZ). Enzymatic
activity of β-galactosidase can be measured by FACS using the fluorescein di-V-
galactoside (FDG) substrate [103]. When FDG gets cleaved by the β-galactosidase
it releases the fluorescent product fluorescein isothiocyanate (FITC). The FITC
signal-intensity can be used as readout for the abundance of Ppef2 on a protein
level since accumulation of the FITC signal is linear and directly correlated to en-
zymatic activity of the β-galactosidase [103]. Therefore, hematopoietic cells of the
spleen of Ppef2−/− lacZ-reporter mice were isolated and lacZ activity measured as
described above (Fig. 4.1 B). Consistent with the findings on mRNA level (Fig.
4.1 A), we detected lacZ activity mostly in CD8+ DCs.
Furthermore, lacZ activity was measured in different cDC subsets of thymus, skin
draining lymph nodes (sLN), lung, lamina propria and the mesenteric lymph no-
des (mLN) (Fig. 4.1 C). cDC populations of lymph nodes were further separated
in resident or migratory cDCs, based on their expression of CD11c and MHCII.
Expression was restricted to CD8+ DCs with the exception for CD11b+ DCs of
the thymus.
Taken together, our data on lacZ protein expression matched the expression profile
of Ppef2 published in the Immgen database (Fig. 3.2 C), with the exception of
CD103+ DCs which did not display lacZ expression in our experiments.
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Figure 4.1: Ppef2 is predominantly expressed by CD8+ DCs. (A) Gene expres-
sion profiling of spleen and blood cells after sorting. Shown is the quantitative real-time
PCR result for Ppef2 of three independent sort experiments (n=3 pooled mice per sort)
analyzed by the 2-∆C’t method [104, 105] with HPRT as housekeeping gene. (B) & (C)
Measurement of lacZ activity by flow cytometry in different cell types of the spleen (B)
and DCs of various other organs (C). Shown are representative FACS-plots with the
corresponding statistics (n=3 mice per group). Statistical analysis was performed using
Student’s t-test, with *: p<0.05, **: p<0.01 and ***: p<0.001.
It was previously shown that Ppef2 expression decreased in BMDCs after stimu-
lation with lipopolysaccharide (LPS) [5]. To test whether this effect was limited
to TLR4 stimulation or whether other TLR ligands would lead to a similar decre-
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ase, we stimulated GM-CSF-generated BMDCs with TLR agonists against TLR4
(LPS), TLR5 (Flagellin), TLR3 (Poly(I:C)), TLR1/2 (Pam3CSK4), and TLR7/8
(CLO97) (Fig. 4.2 A). We also included stimulation with anti-CD40 monoclonal
antibody (mAb), because it was shown that ligation of CD40 led to DC activati-
on, marked by the upregulation of MHCII, costimulatory molecules, and cytokine
production [106, 107]. We also combined the CD40-stimulus with TNFα, since
anti-CD40 antibody alone did not induce DC maturation to an extent similar to
the stimulation with LPS (data not shown). TNFα is commonly used as a matu-
ration agent for DCs [108, 109, 110], and CD40 also belongs to the TNF-receptor
superfamily. Combination of anti-CD40 antibody with TNFα led to high percen-
tages of fully mature DCs, at levels comparable to LPS stimulation. However, the
influence of CD40 on DCs is controversial and some studies claim that the CD40
signal has to be accompanied by TLR stimulus to fully mature DCs [111]. For this
reason, we also combined the anti-CD40 stimulus with the TLR4 stimulus LPS
(Fig. 4.2 A).
Every TLR stimulation tested led to downregulation of Ppef2 expression, where-
as stimulation with anti-CD40 mAb, or the combination of anti-CD40 mAb and
TNFα, did not alter the expression of Ppef2, even when different concentrations of
the antibody were tested in a titration experiment (data not shown). Combining
CD40 and LPS stimulus led to a decrease of Ppef2 expression comparable to LPS
alone.
To broaden this analysis, and because GM-CSF BMDCs do not show the diver-
sity of splenic DCs, we performed the same stimulation experiment in a Ftl3L
dependent BMDC culture (Fig. 4.2 B). Maturation of BMDCs in both culture
conditions was verified by flow cytometric staining of MHCII and CD86 (data
not shown). The Flt3L dependent BMDC culture displayed the same expression
pattern of Ppef2 as the GM-CSF BMDCs for all of the tested stimuli.
To test the differential regulation of Ppef2 expression after DC maturation in vivo,
we took advantage of the lacZ reporter mice described previously. Reporter and
control mice were intravenously injected with 10 µg LPS either 4h (Fig. 4.2 C,
in blue) or ∼16h (Fig. 4.2 C, 16h in black) before sacrifice. Non-reporter control
mice provided the background measurements for detection of lacZ activity in each
experimental group (empty line histograms in Figure 4.2 C). In accordance with
the data obtained in vitro, LPS injection led to rapid downregulation of Ppef2
expression already after 4 hours and decreasing further over time.
In vitro generated GM-CSF BMDCs show to some degree spontaneous maturation
in the absence of stimuli, accompanied by upregulation of MHCII and costimula-
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tory molecules on the surface.
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Figure 4.2: Maturation of DCs leads to downregulation of Ppef2 expression.
(A) Ppef2 expression in GM-CSF BMDCs of C57BL/6 mice 18h after stimulation as
determined by qPCR. Bar graphs with SEM represent pooled data from independently
performed cell cultures (unstim., LPS n=5; Flagellin, Poly(I:C), Pam3CSK4, CLO97,
n=4; antiCD40, LPS+antiCD40, n=3; TNFα+antiCD40, n=2). (B) Expression of Ppef2
(qPCR) in Flt3L BMDCs 18h after addition of LPS, Poly(I:C), or antiCD40 mAb. Bar
graphs with SEM represent pooled data of 3 independently performed cell cultures. (C)
Flow cytometric measurement of lacZ activity in splenic CD8+ DCs. Ppef2−/− reporter
and control Ppef2+/+ mice were injected intravenously with LPS either 4h or the day
before analysis. Shown are representative FACS-plots (open histograms: lacZ-reporter
mice; solid histograms: background from non-reporter controls) and statistics, where the
lacZ signal of reporter mice was subtracted from the lacZ background signal of control
mice who received the same treatment (no LPS, 4h LPS, or o/N LPS). Statistical analysis
was performed on n=3 mice per group using Student’s t-test. (D) Ppef2 expression in
GM-CSF BMDCs of C57BL/6 mice after cell sorting based on the expression of CD11c,
MHCII, and CD86. Unsorted samples containing all three populations were incubated
with or without LPS for 7h. Error bars represent SEM of 3 independent experiments and
statistical analysis was performed using Student’s t-test, with *: p<0.05, **: p<0.01 and
***: p<0.001.
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One possible explanation for this behavior is the disruption of E-cadherin mediated
DC-DC clusters, which was shown to cause this phenotypical maturation. However,
DCs stimulated this way failed to produce immunostimulatory cytokines [112] and
spontaneous maturation within a GM-CSF BMDC culture can have other, possibly
additional, reasons. To evaluate the effect of spontaneous maturation on Ppef2
expression we generated GM-CSF dependent DCs in vitro and sorted CD11c+ DCs
in three populations according to their expression of MHCII and CD86 (Fig. 4.2
D). Ppef2 expression decreased with BMDCs gaining a more (spontaneous) mature
phenotype. Ppef2 expression level of fully mature MHCIIhi CD86hi reflected LPS
matured BMDCs.
Taken together, we detected Ppef2 expression in CD8+ DCs of lymphoid organs
on mRNA level by qPCR of sorted cells and on protein level by lacZ assays.
Expression of Ppef2 decreased when DCs were matured by TLR ligands in vitro
and in vivo as well as in the case of spontaneous maturation in vitro, whereas
maturation of DCs by CD40 ligation did not alter Ppef2 expression.
4.2 Evaluation of Ppef2 deficiency in knockout mice
To further examine the effects of Ppef2 on DC biology we generated KO mice
from embryonic stem cells (JM8A3.N1) produced by EUCOMM. Blastocyst in-
jection into C57BL/6 mice was performed by the Transgenic Core Facility at the
MPI of Molecular Cell Biology and Genetics in Dresden. Since the stem cell line
JM8A3.N1 is of C57BL/6 background but has a agouti coat color, chimerism was
determined by coat color and germline transmission was verified by genotyping
pups of breedings with C57BL/6 mice.
Using the knockout-first approach described in chapter 3.4, we needed to verify
whether homologous recombination was occurring, replacing the endogenous Ppef2
locus (Fig. 4.3 A). We also had to exclude that the promoter driving the neomycin
resistance gene would cause expression of the gene exons located downstream of
the gene trap cassette.
To verify the knockout on transcript level we magnetically enriched CD11c+ spleen
cells and isolated messenger RNA (mRNA). Quantitative PCR of complementary
DNA (cDNA) was performed with intron-spanning primers upstream of the gene
trap, on the the floxed exon 5, or downstream, on exons 11-12 (Fig. 4.3 B).
Compared to Ppef2+/+ control mice, mRNA upstream of the gene trap was de-
creased two-fold, whereas mRNA downstream of the gene trap (spanning the gene
trap or downstream of its polyadenylation signal) was completely absent.
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Figure 4.3: Verification of the Ppef2 knockout on mRNA level. (A) Shown is the
Ppef2 locus with its splicing pattern and different transcripts as stated by the ensembl
project. The knockout-first construct containing the gene trap between exon 4 and 5,
as well as the floxed exon 5, is displayed below. (B) & (C) Ppef2 expression analysis of
whole spleen lysates (B) or CD11c enriched splenocytes (C) in Ppef2+/+ and Ppef2−/−
mice by quantitative real-time PCR. Three sets of intron spanning primer pairs were
used to amplify fragments from exons 2 to 3, 4 to 5 and 11 to 12. The latter corresponds
to the previously shown qPCR experiments of Figure 4.1 and 4.2. The ∆∆Ct Method
was used to calculate the fold expression compared to Ppef2+/+ control samples. Data
was normalized to HPRT. Statistical analysis was performed (n=3 mice) using Student’s
t-test, with *: p<0.05, **: p<0.01 and ***: p<0.001.
4.3 Phenotyping of Ppef2 knockout mice
4.3.1 Phenotyping of Ppef2−/− DCs
Due to its DC specific expression (Fig. 4.1), we hypothesized that Ppef2 may
play a role in DC biology. To analyze for alterations within different DC subsets
we performed flow cytometric analyses of DCs in primary lymphoid organs (Fig.
4.4). Frequencies of DCs in spleen, skin-draining lymph nodes, and thymus were
not influenced by the knockout of Ppef2 (Fig. 4.4 A). Total cell numbers of DC
subpopulations within these primary lymphoid organs were also unaffected by the
loss of Ppef2 (Fig. 4.4 B).
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Figure 4.4: Percentage and total numbers of DC (subpopulations) are not
affected by the loss of Ppef2. (A) DCs of spleen, sLN, and thymus were identified as
CD11c+MHCII+. Shown are representative FACS plots and numbers indicate average
DC percentages ± SEM of pooled data (spleen: n=36 mice; sLN: n=23 mice; thymus:
n=6 mice). (B) Total cell numbers were calculated for DC subtypes of spleen, sLN
and thymus (identified with CD8, CD103 and CD11b) and shown is pooled data ±
SEM (spleen: n=36 mice; sLN: n=23 mice; thymus: n=6 mice). Statistical analysis was
performed using Student’s t-test and all p-values were above 0.05.
Flow cytometric analyses provide information about the frequencies of different
cell populations and consequently their total cell number. However, this does not
consider the local distribution of different cell types and/or splenic microarchi-
tecture. Therefore, we performed histological analyses of spleens of Ppef2+/+ and
Ppef2−/− mice (Fig. 4.5). Splenic microarchitecture was not influenced by the loss
of Ppef2. Analyzed spleen sections of Ppef2−/− mice showed intact T and B cell
zones, a clear staining for the marginal zone (metallophilic macrophages; MOMA),
and DCs that were located in the marginal zone and the T cell zone.
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Figure 4.5: Lack of Ppef2 does not influence splenic microarchitecture. Acetone
fixed spleen sections of Ppef2+/+ and Ppef2−/− mice were stained with antibodies against
CD11c (red), CD8 (green), MOMA (white), and B220 (blue). Scale bars represent 100
µm.
Since DCs of non-lymphoid organs also displayed expression of Ppef2 in the Imm-
gen dataset (Fig. 3.2 C), we isolated DCs from the lung, the lamina propria, the
skin, and the liver, in order to evaluate the effect of the knockout on the DC com-
partments of these non-lymphoid organs (Fig. 4.6). The identification and gating
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of DC (subpopulations) in the non-lymphoid organs was, together with the CD103
surrogate marker CD24, carried out like in [21].
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Figure 4.6: Ppef2 deficiency does not influence the percentage and total num-
ber of DCs in non-lymphoid organs. DCs of lung, lamina propria, and liver were
identified by their expression of CD11c and MHCII after gating on viable CD45+ cells
and further distinguished by their expression of CD8, CD103, CD11b and CD24. DCs
and LCs of the skin were identified by staining for Langerin and MHCII on CD45+ cells.
Dermal cell populations were further distinguished based on Langerin and EpCAM, on
CD45+MHC II+ cells. Monocytes differentiating into macrophages in the gut were dis-
tinguished by the expression of Ly6C and MHCII after gating on viable CD11b+ CD64+
cells as described in [113]. Shown are representative FACS-plots of pooled data (lung
stainings: n=10; lamina propria and skin: n=4; liver: n=10) with the percentages of DCs
± SEM and the corresponding total numbers in the bar graphs below. Statistical analysis
was performed using Student’s t-test. All p-values were above 0.05.
In addition, expression of Ppef2 was also observed on circulating blood monocy-
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tes on mRNA level (Fig. 4.1 A); we therefore wondered whether monocytes, or
monocyte derived macrophages, showed any alterations. To this end, we applied
a staining panel designed by the group of Bernard Malissen [113] to the lamina
propria samples. After gating on viable CD11b+ CD64+ cells, monocytes from the
circulation (gate P1, Fig. 4.6) can be distinguished by their expression of Ly6C
and MHCII on their way to finally become anti-inflammatory macrophages (gate
P3/4, Fig. 4.6). However, we did not observe any changes in DC subsets concerning
their percentage (representative FACS-plots) or their total numbers (bar graphs).
One of the hallmarks of DC biology is the production and secretion of different
kinds of cytokines.
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Figure 4.7: Ppef2−/− mice show a normal cytokine profile. (A) Splenocytes were
stimulated with LPS in vitro for 3h and IL-12 production was measured by intracellular
staining of IL-12 (p40/p70). Cells were gated on viable CD11c+ MHCII+ DCs. Shown
are representative FACS-plots and the corresponding statistics (n=4 mice; Student’s t-
test) in bar graphs. (B) CD11c enriched spleen DCs were cultured for 4h with or without
LPS. The amount of TNF, IL-10 and IL-6 was measured in the supernatant with the
Cytokine Bead Array Kit. Shown is pooled data of two experiments (n=4 mice each).
Statistical analysis was performed using Student’s t-test. All p-values were above 0.05.
Matured cDCs produce the proinflammatory cytokine IL-12 [44] (reviewed in
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[114]), which we also assessed in order to perform a functional phenotyping of
the Ppef2−/− mice. To test the ability of splenic DCs to produce IL-12, we iso-
lated splenocytes and cultured them for three hours, with or without addition of
LPS. We used a fluorescently labeled antibody detecting the p40 monomer and
p70 heterodimer of IL-12 for intracellular staining.
Addition of LPS increased the level of IL-12 measured by flow cytometry both in
the Ppef2+/+ and Ppef2−/− DCs (Fig. 4.7 A). Production and secretion of TNF,
IL-10, and IL-6 was measured by culturing magnetically enriched CD11c+ spleno-
cytes with or without the addition of LPS. Secreted cytokines were measured by
cytokine bead array on the collected supernatants. Addition of LPS led in all cases
to an increase in secreted cytokines (Fig. 4.7 B), and no significant difference was
observed between mice lacking Ppef2 and controls.
4.3.2 Phenotyping of other haematopoietic cells
Although Ppef2 expression seemed, within the haematopoietic system, to be limi-
ted to CD8+ DCs, we sought to rule out whether the complete knockout used in
this study has any impact on the abundance of other immune cells. Together with
the Centre d’Immunophénomique (CIPHE) we performed a high-throughput flow
cytometry analysis to measure several different cell types at once in the spleens of
Ppef2+/+ and Ppef2−/− mice (Fig. 4.8). To highlight systematic differences across
all populations, hierarchical clustering was performed (Fig. 4.8 A). The lack of
defined clustering among Ppef2+/+ and Ppef2−/− samples within cell populations,
as well as among samples, indicates that absence of Ppef2 does not impact specific
cell “families”. However, this does not rule out the possibility that only one or a
few cell types, independent of each other, are affected. To evaluate each cell type
individually, we looked at their percentages (Fig. 4.8 B) and total cell number
(Fig. 4.8 C). The lack of Ppef2 did not significantly influence the abundance of
any cell type investigated.
Taken together, the lack of Ppef2 did neither affect the abundance of cDCs in
lymphoid and non-lymphoid organs, nor the frequency of other hematopoietic
cells investigated. Histological analysis of spleens also revealed an intact spleen
microarchitecture with cDCs confined to the marginal zone and the T cell zone.
Functionally, Ppef2−/− DCs were still able to produce cytokines after stimulation
at levels comparable to Ppef2+/+ DCs.
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Figure 4.8: Phenotyping of hematopoietic cells does not show abnor-
malities. Spleens of Ppef2+/+ or Ppef2−/− mice were analyzed by the Centre
d‘Immunophénomique (CIPHE) for various cell populations by flow cytometry (n=6
mice per group). The marker used for the identification of every population is listed
in section 6.2.1.3. (A) Hierarchical clustering (HC) analysis of all 56 parameters tested
in two different staining panels. THE Dataset was therefore imported into TIGR Mul-
tiExperiment Viewer (TMeV), normalized based on the median value of each row and
reduced based on the SD of the values of the given row. A hierarchical clustering tree
was built based on these signal intensities (Euclidean Complete). (B) Radar plot of the
frequencies of different (sub-) populations (as percent of total or percent of parent, indi-
cated in squared brackets) and their corresponding total cell numbers (C). Analysis was
performed with cohoused groups of six mice.
4.4 Analysis of apoptosis in Ppef2−/− animals
Although Ppef2−/− mice did not display any change, neither in the abundance of
DCs nor in the spleen microarchitecture, we wondered whether cDCs might be
more prone to apoptosis, as suggested by previous studies on the role of Ppef2 in
vitro in different cell lines [97].
4.4.1 Apoptosis in vitro
To address the question of enhanced susceptibility to apoptosis, we performed
GM-CSF BMDC cultures from Ppef2+/+ and Ppef2−/− mice. After six days of
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culture, growth factor was removed and survival of DCs was monitored by flow
cytometry for the following six days (Fig. 4.9 A).
As long as BMDCs were cultured in the presence of GM-CSF (Fig. 4.9 A; days
-6 to 0), Ppef2+/+ and Ppef2−/− DCs showed normal frequencies and survival, as
shown in Figure 4.9 B (day 0 without GM-CSF). However, at the first day after
GM-CSF withdrawal both BMDC cultures showed an increase in the percentage of
viable DCs, although the frequency of Ppef2−/− BMDCs was decreased compared
to control. This reduction of viable Ppef2−/− DCs was maintained the following
days of culture until day six, where the amount of living Ppef2+/+ and Ppef2−/−
DCs were identical.
In relation to the increase in viable DCs one day after the removal of GM-CSF,
we wondered whether the observed discrepancy in viability between Ppef2+/+ and
Ppef2−/− DCs could be due to differences in proliferation rather than apoptosis.
To this end, we analyzed proliferation by adding BrdU to the culture at day 0 of
GM-CSF withdrawal. BrdU incorporation was measured the following day (day
1 after removal of growth factor) by flow cytometry (Fig. 4.9 C). Approximately
20% of both, Ppef2+/+ and Ppef2−/− DCs, incorporated BrdU into the DNA. This
made changes in proliferation after GM-CSF removal unlikely and we went on to
look for apoptotic alterations.
The cleavage of caspase-3, a critical player of the execution-phase of cell apop-
tosis, is necessary for its activation and function. This cleavage can be used as a
measure of apoptotic activity, by means of intracellular staining with antibodies
targeting specifically the cleaved subunit. In our experiment, this staining revealed
an increase in active caspase-3 after removal of growth factor in both, Ppef2+/+
and Ppef2−/− BMDCs (Fig. 4.9 D). However, Ppef2 deficiency resulted in a signi-
ficantly higher increase in cleaved caspase-3 when compared to Ppef2+/+ control
BMDCs. The increase caused by Ppef2 deficiency was not visible with normal
culture conditions in the presence of GM-CSF (day 0).
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Figure 4.9: Ppef2−/− GM-CSF BMDCs are more prone to apoptosis after
growth factor withdrawal. (A) Survival of Ppef2+/+ and Ppef2−/− in vitro generated
GM-CSF BMDCs after withdrawal of growth factor. BMDCs were extensively washed
after 6 days (“day 0”) and 2·106 cells were again plated in a 6 well plate with 3 ml
of medium lacking GM-CSF. (B) The amount of viable CD11c+ MHCII+ DCs was
monitored over time by FACS analysis. Representative result of 3 repetitions with n=3
mice. (C) At day 0 of GM-CSF withdrawal 5-bromo-2’-deoxyuridine (BrdU) was added
to the culture at final concentration of 1mM. BrdU incorporation was monitored the
following day by FACS analysis (n=3). (D) Intracellular staining of cleaved caspase-3
in day 0 (of GM-CSF withdrawal) CD11c+ MHCII+ BMDCs or BMDCs after one day
of GM-CSF withdrawal (n=3). (E) Annexin-V staining of in vitro generated CD11c+
MHCII+ DCs after withdrawal of GM-CSF (n=3). Statistical analysis was performed
using Student’s t-test, with **: p<0.01 and ***: p<0.001.
Caspase-3 activation is an early event of apoptosis and lastly leading to several
cellular changes. One of them is the exposure of phosphatidylserine on the outer
plasma membrane leaflet. This translocation of phosphatidylserine from the in-
ner to the outer membrane leaflet promotes phagocytosis of apoptotic cells and
can be stained with the phosphatidylserine-binding protein Annexin-V [115] as a
marker of early and late apoptosis. Staining of phosphatidylserine on BMDCs at
day 0 or day 1 without GM-CSF reflected the active caspase-3 staining and in-
creased in both groups after removal of the growth factor. However, this increase
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in phosphatidylserine on the cell surface was elevated after loss of Ppef2 (Fig. 4.9
E).
4.4.2 Apoptosis ex vivo
We asked whether these findings also hold true for ex vivo sorted, primary spleno-
cytes. To this end, we isolated splenocytes from Ppef2+/+ and Ppef2−/− mice and
magnetically purified the CD11c+ cells. Cleaved caspase-3 staining was used as a
readout for apoptosis after culturing the enriched DCs over night with or without
GM-CSF (Fig. 4.10 A).
Gating on all viable cDCs, without differentiating subpopulations (Fig. 4.10 B),
revealed that the lack of growth factor caused an increase of cleaved caspase-3 in
both Ppef2−/− and control mice. However, cDCs of Ppef2−/− mice showed higher
levels of active caspase-3 compared to Ppef2+/+ control mice. Concomitantly, the
percentage of viable cDCs was also reduced compared to control.
To broaden this analysis, we discriminated the CD8+ (Fig. 4.10 B) and CD11b+
(Fig. 4.10 C) DC subpopulations. Already in the presence of growth factor, control
and Ppef2−/− mice showed more caspase-3 activity in CD8+ compared to CD11b+
DCs (Fig. 4.10 B and C). The general increase of cleaved caspase-3 without GM-
CSF was more pronounced in CD11b+ DCs (Fig. 4.10 C) than in CD8+ DCs (Fig.
4.10 B). Nevertheless, both cDC subpopulation showed more active caspase-3 in
the knockout condition compared to wild type after cytokine withdrawal. In line
with this result, the frequency of viable Ppef2−/− cells was reduced in both cDCs
subsets, although this difference was more pronounced in the CD8+ DCs.
Because of the restricted expression pattern of Ppef2 (Fig. 3.2 and 4.1), which
showed almost no expression in CD11b+ DCs, we wondered whether a soluble
factor secreted by CD8+ DCs might be the cause of elevated caspase activity in
CD11b+ DCs, lacking Ppef2. To this end, we sorted spleen CD8+ DCs of Ppef2+/+
and Ppef2−/− mice and kept in culture over night, with or without the addition of
GM-CSF (Fig. 4.10 E). The following day, the supernatants of these cultures were
collected and sorted splenic CD11b+ DCs of Ppef2+/+ mice were cultured with
either the supernatant of the Ppef2+/+ or Ppef2−/− CD8+ DCs. In accordance
with previous results, medium lacking GM-CSF led to increased caspase activity
but the source of supernatant, Ppef2+/+ or Ppef2−/− CD8+ DCs, had no effect on
the extent of this increase (Fig. 4.10 F).
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Figure 4.10: Ppef2−/− ex vivo cultured splenic DCs show an increase in apop-
tosis. (A) Spleen DCs of Ppef2+/+ or Ppef2−/− mice were purified by magnetic labeling
and cultured overnight in the presence or absence of GM-CSF. DCs were intracellularly
stained for cleaved caspase-3 and analyzed by flow cytometry, gated either on all CD11c+
MHCII+ (B), on the CD8+ DCs (C), or on the CD11b+ DCs (D). Shown are represen-
tative FACS-plots of n=3 mice. (E) Ppef2+/+ or Ppef2−/− magnetically purified CD8+
DCs were cultured overnight with or without GM-CSF. The next day, Ppef2+/+ CD11b+
DCs were FACS sorted and cultured overnight with the supernatant of the Ppef2+/+ or
Ppef2−/− CD8+ DCs. Caspase-3 activity was measured by intracellular staining of clea-
ved caspase-3 (F). Shown is combined data of two experiments. Statistical analysis was
performed using Student’s t-test, with *: p<0.05 and **: p<0.01.
4.4.3 Apoptosis in vivo
After observing an increased susceptibility to apoptosis in vitro and ex vivo, we
wondered whether this effects are truly dependent of GM-CSF or are also detec-
table in a more physiological environment in vivo, where GM-CSF is known to
be dispensable for the development and homeostasis of DCs in lymphoid organs
[20]. Therefore we isolated spleen cells of Ppef2+/+ and Ppef2−/− mice and stai-
ned intracellular, active caspase-3. Flow cytometric analyses revealed an increase
of active caspase-3 in Ppef2−/− cDCs compared to control cDCs (Fig. 4.11 A).
Surprisingly, we could observe this increase in both cDCs subsets of the spleen,
CD8+ and CD11b+ DCs, although CD8+ DCs showed generally more caspase ac-
tivity than CD11b+ DCs. Since Ppef2 expression was limited to DCs, we checked
whether the observed increase in caspase activity was truly specific for DCs by
also staining other cells of the haematopoietic system (Fig. 4.11 B). Caspase-3
activity was highest in pDCs and only marginally detectable in B cells, (CD4+
and CD8+) T cells, macrophages, and monocytes of the spleen. However, in none
of the cell types investigated we found a statistically significant increase of cleaved
caspase-3 in Ppef2−/− mice.
Furthermore, we performed Annexin-V stainings to also examine later stages of
apoptosis than those observed with cleaved caspase-3 staining (Fig. 4.11 C). We
found that the frequency of Annexin-V+ Ppef2−/− cells was elevated in CD8+ and
CD11b+ DCs.
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Figure 4.11: Loss of Ppef2 leads to an increase of apoptotic DCs in vivo. (A)
Spleen DCs were intracellular stained for cleaved caspase-3 and analyzed by flow cytome-
try. Shown are representative FACS-plots of two experiments (with n=4 mice each) and
the corresponding pooled statistics. (B) Analysis of cleaved caspase-3 in different spleen
subsets (n=4 mice). (C) Annexin-V staining of spleen DCs defined as viable CD11c+
MHCII+. Shown are representative FACS-plots of n=5 mice and the corresponding sta-
tistics. All statistical analyses were performed using Student’s t-test, with *: p<0.05 and
**: p<0.01.
Taken together, Ppef2−/− DCs showed an increase in apoptosis in vitro and ex
vivo when not supplied optimally with growth factor. This was also seen in vivo
with freshly isolated spleen CD8+ and CD11b+ cDCs.
4.5 Mixed chimeras
Congenic animals differ in only one locus and a linked segment of chromosome but
are otherwise genetically identical. CD45.1 and CD45.2 are congenic variants of
CD45 and can be used to identify cells of distinct origins in transfer experiments.
To test whether the increase in apoptosis would lead to a disadvantage of Ppef2−/−
DCs in a competitive situation we reconstituted lethally irradiated Ppef2+/+ mice
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(CD45.1) with a 1:1 bone marrow mixture derived from Ppef2+/+ (CD45.1) and
Ppef2−/− (CD45.2) mice (Fig. 4.12 A). In such mixed bone marrow chimeras hae-
matopoietic Ppef2+/+ derived cells and non-haematopoietic cells of the recipient
can provide all extrinsic factors like cytokines. This allows to investigate whether
the observed increase in apoptosis is an intrinsic or extrinsic effect for CD8+ and
CD11b+ DCs, respectively.
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Figure 4.12: Ppef2−/− DCs have a disadvantage in a competitive situation.
(A) Mixed bone marrow chimeras were produced by reconstitution of irradiated CD45.1+
recipients with mixed CD45.1+ and CD45.2+ bone marrow of either Ppef2+/+ mice, or
Ppef2+/+ and Ppef2−/− mice. (B) Mixed bone marrow chimera were analyzed earliest
at 6 weeks after reconstitution by staining of CD45.1. DCs of the spleen were identified
by staining of CD11c and MHCII and DCs subsets were distinguished by staining of
CD8 and CD11b. FACS-plots shown are representative of three independently performed
experiments with similar outcome (n=11). (C) The ratios of CD45.2+ to CD45.1+ DCs
were calculated and statistical analysis was performed using Student’s t-test, with **:
p<0.01.
Analyses of the congenic composition of splenic CD8+ DCs revealed that DCs of
Ppef2−/− origin showed a disadvantage compared to Ppef2+/+ DCs (Fig. 4.12 B).
On the other hand, the congenic distribution in CD11b+ DCs was not altered
compared to control chimeras, that received a mixture of Ppef2+/+ bone marrow
(Fig. 4.12 B). Statistical analysis was performed calculating the ratio between DCs
of CD45.2 (Ppef2−/−) and CD45.1 (Ppef2+/+) origin to determine the chimerism.
Those ratios were compared to control chimeras (Fig. 4.12 C). CD8+ DCs showed a
29.78% reduction in the ratio, whereas CD11b+ DCs did not display any significant
changes, arguing for a CD8+ DC intrinsic effect of Ppef2, as assumed by the
expression pattern of Ppef2 (Fig. 4.1).
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4.6 Analysis of DC proliferation and turnover
We observed that Ppef2 deficiency led to increased susceptibility to apoptosis if
not supplied optimally with growth factor in vitro, as well as ex vivo. Further-
more, Ppef2−/− DC of the spleen also showed an increase in apoptosis in vivo.
Intriguingly, we did not observe any changes in DC numbers or percentages in
various organs, albeit the observed increase in apoptosis. This led us to the ques-
tion, whether Ppef2 deficiency also leads to an increase in proliferation of DCs to
compensate for their increased apoptosis. To analyze in vivo proliferation of DCs
we performed BrdU pulse-chase experiments with an initial bolus of intraperito-
neally applied BrdU, followed by administration of BrdU in the drinking water
for three consecutive days. During this so called “pulse phase” newly dividing cells
incorporate the thymidine analog into the Deoxyribonucleic acid (DNA). After
these three days of pulsing, mice were again given normal drinking water and Br-
dU labeling was followed for another 9 days. When BrdU supply stops and BrdU
gets cleared out of the system, the decrease of BrdU positive cells corresponds
to cell turnover in the “chase phase”. Investigating the effect of cDC proliferation
in the “pulse phase” (Fig. 4.13 A) showed inconsistent results. In one experiment
(filled blue and open blue data-points) we observed an increase in DC proliferation
at day 3, although more pronounced on CD11b+ DCs compared to CD8+ DCs.
In another repetition we saw effects on day 9 rather then day 3. In particular we
observed a reduced percentage of BrdU+ Ppef2−/− DCs. However, pooling the two
individually performed experiments did not highlight any statistically significant
differences when it comes to BrdU incorporation or turnover.
To focus on the BrdU incorporation “pulse phase” we also performed short time
BrdU labeling, where mice were sacrificed two hours after intraperitoneal injection
of 1 mg BrdU (Fig. 4.13 B). Also this experiment displayed contradictory data
and did not show any significant differences between Ppef2+/+ and Ppef2−/− DCs,
when data from three experiments were pooled.
cDCs and their precursors are well known consumers of Flt3L and we therefore
wondered whether the increase in apoptotic DCs in Ppef2−/− would lead to incre-
ased Flt3L levels in the serum, which was seen in some mouse models with reduced
cDC numbers [116, 117]. To this end, we performed an ELISA to test whether the
observed increase in apoptosis translates in changes of the serum level of Flt3L in
Ppef2+/+ and Ppef2−/− mice (Fig. 4.13 C).
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Figure 4.13: Analysis of DC proliferation and turnover. (A) Ppef2+/+ and
Ppef2−/− mice were injected i.p. with 1 mg of BrdU and given 0.8 mg/ml BrdU in
the drinking water for three consecutive days. After that mice were switched back to
normal drinking water and BrdU turnover was followed for another 9 days. Shown is the
pooled data of two different experiments (n=3 each) (on day 3 and 9) or one experi-
ment (n=3 on day 6 and 12). Filled and open blue data-points indicate one experiment,
whereas filled and open red represents a second experiment. (B) Mice were injected i.p.
with 1 mg of BrdU and sacrificed 2h after injection. Shown is pooled data from three
experiments (with n=11 mice in total). (C) Serum level of Flt3L was measured by ELISA
(n=11). (D) Protein level of Flt3 was measured by extra- and intracellular staining of
the receptor in spleen cDCs. Shown are representative FACS-plots of three experiments
with n=4 mice each. (E) and (F) The frequency of DC precursors was determined for
spleen and bone marrow (n=3 for (E) and n=4 for (F)), together with their expression
of lacZ. (E) Flt3 surface expression was measured on splenic DC precursors. Statistical
analysis was performed using Student’s t-test, with *: p<0.05.
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We found only a small tendency of increased Flt3L in the serum with a p-value
of 0.0735 (Fig. 4.13 C). However, once Flt3L binds to its receptor, Flt3 forms a
homodimer and the whole complex gets internalized starting within 5 minutes of
ligation and reaching a maximum after 15 minutes, leading to rapid degradation
[118]. Because of the trend observed in serum Flt3L, we wondered whether DCs
or their precursors might display differences in the expression of the receptor Flt3,
which could sum up with the tendency in serum Flt3L. To this end, we performed
surface and intracellular stainings of the receptor on spleen cDCs (Fig. 4.13 D).
Because of the role of Flt3 in the development of DCs [19] we investigated its
expression on DC precursors of the spleen (Fig. 4.13 E). To exclude effects caused
by differences in DC precursors we checked their frequency and their expression of
Ppef2 by performing a lacZ-FACS-assay in the spleen (Fig. 4.13 E) and the bone
marrow (Fig. 4.13 F). No major differences between Ppef2+/+ or Ppef2−/− cDCs
or their precursors were detected.
Taken together, BrdU incorporation experiments did not show any changes in DC
proliferation which would compensate for the increased apoptosis. Serum levels of
Flt3L were normal, as well as the surface expression of its receptor (Flt3) on cDC
precursors and terminally differentiated cDCs.
4.7 In vivo antigen presentation
Since it was already shown that the life-span of DCs directly influences the priming
of T cells [1], we wondered whether the increase in DC apoptosis would lead to
a diminished T cell activation under limiting conditions. To this end, we took
advantage of OT-I cells, which are monoclonal CD8+ T cells that carry a transgenic
T cell receptor which specifically recognizes the OVA257–264 peptide SIINFEKL in
the context of H2-Kb. We adoptively transferred OT-I T cells into Ppef2+/+ or
Ppef2−/− host mice and injected the mice OVA protein one day later. Mice were
then sacrificed three days later at the peak of OT-I proliferation and spleens were
analyzed by flow cytometry (Fig. 4.14 A and B).
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Figure 4.14: In vivo antigen presentation. 5·105 congenically marked (CD90.1)
OT-I T cells were adoptively transferred either in Ppef2+/+ or Ppef2−/− mice, which
received 100 µg OVA protein intravenously one day later. Mice were sacrificed three
days after OVA administration and spleens were analyzed by flow cytometry for OT-I
T cell proliferation. Shown are representative FACS-plots of OT-I T cells (A). (B) Two
independent experiments (with n=3 mice each) were pooled by calculating the percent
of WT for the percentage and total cell number of OT-I T cells. (C) and (D) 1.5·105
Ppef2+/+ or Ppef2−/− DCs were pulsed with OVA peptide (SIINFEKL) and transferred
into Kbm1 recipient mice. 24 h later Kbm1 OT-I T cells were transferred and mice were
analyzed 3 days later for OT-I T cell proliferation by flow cytometry. (C) Shown are
representative FACS-plots of the gated OT-I T cells. (D) Two different independently
performed experiments (with n=3 mice each) were pooled by calculating the percent
of WT for total cell number and percentage of OT-I T cells. Statistical analysis was
performed using Student’s t-test, with *: p<0.05, **: p<0.01 and ***: p<0.001.
Transferred OT-I T cells were identified by their surface expression of CD8 and
the congenic marker CD90.1 (Fig. 4.14 A). Mice lacking Ppef2 showed a 28% re-
duction in the percentage of OT-I T cells and a 38% reduction in the total cell
number of OVA specific T cells (Fig. 4.14 B).
As this effect can be explained by several different reasons, like defects in OVA
protein uptake, processing of antigen, MHC loading, and proper presentation of
antigen, we wanted to exclude some of these factors by transferring peptide pulsed
DCs in Kbm1 recipient mice. Pulsing DCs with the OVA peptide SIINFEKL avo-
ids the need of protein processing and using Kbm1 mice as recipients bypasses the
possibility that the peptide is presented by any other cell type of the host mice,
as the bm1 mutation of the H2-Kb gene leads to a failure to present SIINFEKL
on MHCI [119].
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To this end, we isolated cDCs of Ppef2+/+ or Ppef2−/− mice that were previously
expanded in vivo by administering a Flt3L secreting tumor cell line. 1.5 · 105 ma-
gnetically enriched cDCs were then pulsed with SIINFEKL for one hour in vitro
and transferred into Kbm1 recipient mice. One day after the transfer, recipient mice
received 105 congenitally marked (CD45.1) Kbm1 OT-I T cells, and mice were ana-
lyzed by flow cytometry three days after OT-I transfer. OT-I T cell proliferation
was assessed by gating on CD8+ CD45.1+ T cells (Fig. 4.14 C) and calculating the
percentage and total number of OT-I cells in the spleen (Fig. 4.14 D). The per-
centage of OT-I T cells was reduced by 38.2% in the mice that received Ppef2−/−
peptide-pulsed DCs compared to control and the total cell number of OT-I cells
were reduced by half (49.1%).
In conclusion, we were able to show that Ppef2 influences the transient T cell acti-
vation, as transfer of SIINFEKL-pulsed Ppef2−/− DCs resulted in reduced numbers
and frequencies of antigen specific T cells. The same was seen for cross-primed T
cells when full OVA protein was injected in Ppef2−/− mice.
4.8 mRNA sequencing and western blot analysis of
Ppef2−/− DCs
To understand mechanistically how Ppef2 might influence DC survival, we conduc-
ted mRNA sequencing of sorted spleen cDCs (Fig. 4.15). FACS-sorting of Ppef2+/+
and Ppef2−/− splenocytes was performed according to the gating strategy depicted
in Figure 4.15 A. After gating on living lymphocytes, excluding cell aggregates,
we identified cDCs as CD11c+ MHCII+ and distinguished cDC subpopulations
according to their expression of CD8 and CD11b.
A total of 10766 genes were detected in CD8+ DCs and 10947 in CD11b+ DCs.
The read counts for Ppef2 in the two subsets were used as internal control for sor-
ting and genotype (Fig. 4.15 B). Ppef2+/+ mice showed about 200 reads of Ppef2
in the sorted CD8+ but not in the CD11b+ DCs, whereas the sorted Ppef2−/−
DCs did not show any reads above background, neither in the CD8+ nor in the
CD11b+ DCs.
Analysis of differentially expressed genes in the CD8+ DC compartment (Fig. 4.15
C) revealed 13 genes that were downregulated compared to control, and 8 genes
that were upregulated more than at least two-fold with a p-value ≤ 0.01. Ppef2
showed the strongest downregulation (84.4 fold compared to control), followed
by an uncharacterized transcript (LOC100503496), which was downregulated 9.2
fold.
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Figure 4.15: mRNA sequencing of sorted splenic DCs and verification by
qPCR. (A) Splenic CD8+ and CD11b+ DCs were FACS sorted five times independently
with ≥3 pooled mice per group. The average sort purity of all 5 sorts reached ≥95% for
each sample. RNA processing and sequencing was performed by the group of Joachim
Schultze (LIMES, Bonn). (B) The reads of Ppef2 served as internal control. (C) & (D)
Volcano plot analyses of sorted DC subpopulations. Fold change of -2 and +2, and a
p-value ≤0.01 were chosen as cut-off. qPCRs of another three independently performed
sorts were done for Trim2 (E) and Dll4 (F). Statistical analysis was performed using
Student’s t-test, with *: p<0.05, **: p<0.01 and ***: p<0.001.
The other significantly downregulated genes were Xlr4c, Dll4, Trim2, Npcd,
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Mfsd2b, Cmah, Xntrpc, Gpr19, A530064D06Rik, 1810014B01Rik, and Triqk.
Among the upregulated genes, Nptxr was the highest, with a 3.3 fold increase,
followed by Rasd1, Gfra2, Rmi2, Thsd1, Ccl2, Zfp772, and Cenpw.
Although CD11b+ DCs do not express Ppef2 and effects showed for the CD11b+
DCs were indirect rather than intrinsic effects, we also performed mRNA sequen-
cing on sorted CD11b+ DCs of the spleen (Fig. 4.15 D). The volcano plot analysis
displayed, showed five downregulated and six upregulated transcripts. Among the
reduced transcripts, Trim34b was the most downregulated, with an 8.1-fold reduc-
tion. Tspan32, Gm21992, Ispd, and Rnmtl1 were downregulated between 3.2 to
2.1 fold. From the six upregulated transcripts, Dynlt1f (3.7 fold) was the one with
the highest increase. Zfp964, Tmem170, Wfikkn1, Tmsb15b1, and Acad12 were
increased between 2.4 to 2.1 fold.
In CD8+ DCs, Trim2 was downregulated 2.5 fold; this gene is of particular inte-
rest because it is known to bind to the pro-apoptotic protein Bim, mediating the
p42/p44 MAP kinase-dependent ubiquitination of Bim [120].
To validate the mRNA sequencing results, we performed a qPCR of Trim2 on sor-
ted DC subpopulations of the spleen (Fig. 4.15 E). The results showed a reduction
of 14.3% in CD8+ DCs compared to control, whereas expression of Trim2 was not
altered in CD11b+ DCs.
Dll4 was downregulated 2.8 fold in the mRNA sequencing of CD8+ DCs and is
a ligand of Notch1 and Notch4 [121]. Notch signaling is known to be crucial for
lymphocyte development and function (reviewed in [122]). It was also shown that
signaling via Notch is crucial for the maintenance of CD8− DCs [29]. Therefore,
we also verified the downregulation of the Dll4 transcript by qPCR (Fig. 4.15 F).
Compared to control, Dll4 expression was reduced 47.4% in Ppef2−/− CD8+ DCs,
whereas expression was not altered in CD11b+ DCs.
To test whether the decrease of Trim2 mRNA could be the driver of apoptosis by
a pathway leading to accumulation of pro-apoptotic Bim, we performed western
blot analyses of Bim in GM-CSF BMDCs (Fig. 4.16 A & B) and primary sorted
spleen DCs (Fig. 4.16 C & D). We also performed FACS analysis of Dll4 to test
whether the altered expression of Dll4 would translate into changed amounts of
protein.
44
4.8 mRNA sequencing and western blot analysis of Ppef2−/− DCs
15
25
35
kDa - + - + LPS
Ppef2+/+ Ppef2-/-
BimEL
BimL
0
1
2
3
4
BimEL
BimL
BimS
fo
ld
 in
cr
ea
se
 in
te
ns
ity
Ppef2+/+ Ppef2-/-
+LPS-LPS +LPS-LPS
A B C
0 103 104 1050 103 104 1050 103 104 105
0
20
40
60
80
100
CD8+ DCs CD11b+ DCs pDCs
isotype
Ppef2+/+
Ppef2-/-
Dll4
%
 o
f M
ax
.
CD8+ DCs CD11b+ DCs pDCs
0
100
200
300
400
Ppef2+/+
Ppef2-/-
M
FI
 D
ll4
E
15
25
35
25
55
BimEL
BimL
BimS
GAPDH
+/+ -/- -/-+/+
CD8+ CD11b+
25
15
25
15
kDa
BimEL
BimEL
BimL
BimL
BimS
25
35 GAPDH
CD8+ DCs
BimEL
0.0
0.5
1.0
1.5
2.0
in
te
ns
ity
BimL BimS
+/+
-/-
CD11b+ DCs
0
1
2
3
16
18
20
in
te
ns
ity
BimEL BimL BimS
D
Figure 4.16: Analysis of pro-apoptotic Bim and Dll4 on protein level. (A)
Western blot for Bim was performed with 30 µg cell lysates of GM-CSF BMDCs either
unstimulated or LPS matured. The membrane was exposed for 30 seconds to detect gra-
dual levels of the BimEL and BimL isoforms. To detect the BimS isoform the membrane
was exposed for 5 minutes. GAPDH with an exposure time of less than a second served
as loading control. (B) Intensities of the bands for all three Bim isoforms were quantified
relative to the GAPDH loading control by using ImageJ and fold increase was calcula-
ted relative to the untreated Ppef2+/+ control. Two western blots were performed and
shown is the pooled normalized intensity of both. (C) Western blot for Bim was per-
formed with 30 µg cell lysates of FACS-sorted CD8+ and CD11b+ DCs of the spleen
of Ppef2+/+ and Ppef2−/− mice. Exposure of the membrane was performed like in (A).
(D) Intensities of the bands for all three Bim isoforms were quantified relative to the
GAPDH loading control by using ImageJ and fold increase was calculated relative to the
untreated Ppef2+/+ control. Shown is the result of one experiment with pooled samples
of three mice per group. (E) Surface staining of Dll4 was performed with fluorescently
labeled antibody and protein abundance was measured by flow cytometry. Shown are
representative FACS plots of n=3 mice.
It was shown previously that cytoplasmic Bim increases after stimulation with
TLR ligands like LPS [86]. Therefore we stimulated parts of the BMDC culture
over night with LPS as positive control for an increase of Bim, which comes in
three isoforms: BimEL, BimL, and BimS. All three isoforms are generated by al-
ternative splicing and are promoting apoptosis [123]. The shortest isoform, BimS,
is the most cytotoxic and only transiently expressed during apoptosis. Due to the
different abundance of the three Bim isoforms the western blot was exposed either
30 seconds for detection of the larger and more abundant isoforms BimEL and
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BimL, or 5 minutes for detection of the small isoform BimS (Fig. 4.16 A & C).
GAPDH was used as loading control for every sample with an exposure of less
than a second to not get a fully saturated signal. To quantify the increase in Bim
protein, the intensities of the western blot bands were quantified and normalized
to the intensities of the respective GAPDH bands. Fold increase of Bim protein
was then calculated relative to Ppef2+/+ (non LPS-treated) DCs for each Bim
isotype respectively (Fig. 4.16 B & D). The intensity of all of the three Bim iso-
forms increased in the Ppef2−/− BMDCs compared to control. This increase was
comparable to the increase caused by LPS in Ppef2+/+ BMDCs. Stimulation of
Ppef2−/− DCs with LPS increased cytoplasmic Bim only marginally (Fig. 4.16
B). Also in primary spleen cDCs protein abundance of all three Bim isoforms was
increased in Ppef2−/− CD8+ and CD11b+ DCs (Fig. 4.16 C & D).
Although expression of Dll4 is generally low in cDCs but high in pDCs (imm-
gen.org), we saw alterations of expression in CD8+ cDCs of Ppef2−/− mice (Fig.
4.15 C & F). Therefore, we performed surface stainings with an antibody directed
against Dll4 (Fig. 4.16 D). In accordance with the expression profile of Dll4, splenic
cDCs showed only minor staining compared to an isotype control, whereas pDCs
showed a clear staining of Dll4. However, Ppef2+/+ and Ppef2−/− DCs showed the
same extent of Dll4 staining and the difference in expression was not seen on a
(surface) protein level.
In conclusion, we detected decreased Trim2 mRNA by mRNA sequencing of
Ppef2−/− CD8+ DCs, which we were able to verify by qPCR. Trim2 is known
to influence the protein abundance of pro-apoptotic Bim, which was upregulated
in Ppef2−/− BMDCs and splenic DCs.
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5 Discussion
Currently very little is known about Ppef2. In this project we were able to show
that haematopoietic cells express this phosphatase in a CD8+ DC specific manner
and that expression is changed upon maturation of DCs. By generating Ppef2−/−
mice we were the first to demonstrate a role of Ppef2 in DC biology. We were able
to show that Ppef2 controls DC apoptosis by mechanisms involving Trim2 and
Bim, influencing the priming of naive T cells.
5.1 Ppef2 is preferentially expressed by CD8+ DCs
Previous work by our group identified a transcription factor binding motif in the
promoter region of CD11c, that is responsible for driving expression of DC specific
genes. An in silico search for other genes with the same promoter module iden-
tified Ppef2 as gene potentially expressed in a DC specific manner. To test this,
we purified DCs, T cells, and B cells of the spleen, as well as circulating blood
monocytes. Ppef2 expression, as determined by qPCR, was highest in CD8+ DCs,
with an 17.7 fold increase compared to ESAMlo DCs. With a 2-∆C’t value of 0.04,
the expression in ESAMlo DCs was similar to blood monocytes (0.03 to 0.05).
pDCs, CD4+, and CD8+ T cells showed a 2-∆C’t value of less than 0.003, which
can be seen as background (Fig. 4.1 A). As the expression in ESAMlo DCs and
monocytes is also very modest and close to background, it is hard to say whether
the expression measured here is of biological significance, or not. Interestingly,
ESAMlo DCs are supposed to be more closely related to monocytes than to cDCs,
as they express several monocyte related genes [18]. Overall, the expression pro-
file of Ppef2 in sorted spleen cells reflected the microarray data available from
the Immgen consortium (Fig. 3.2 B), showing Ppef2 expression largely specific for
CD8+ DCs.
The abundance of a certain transcript does not necessarily predict protein quan-
tity. As shown by several genome-wide studies, only about 40% of the variation in
protein concentration can be explained by knowing mRNA abundance [124, 125].
To further elucidate the expression profile of Ppef2 at the protein level, we took ad-
vantage of the β-galactosidase (lacZ) included in the gene trap cassette of Ppef2−/−
mice (Fig. 3.3). In the spleen, lacZ activity was only measured in CD8+ DCs, but
not in ESAMlo DCs, ESAMhi DCs, pDCs, CD4+ T cells, CD8+ T cells, B cells,
monocytes, and neutrophils (Fig. 4.1 B). Thus we can conclude that expression
of Ppef2 mRNA in ESAMlo DCs and monocytes (Fig. 4.1 A) is indistinguishable
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from background, or that it is not translated into biologically relevant amount of
protein. However, due to technical limitations of the lacZ assay we can not rule
out to not miss very small amounts of protein being expressed. Checking Ppef2
on protein level by other methods, e.g. by western blot, was not possible due to a
lack of a functional antibody against Ppef2.
Due to the fact that the CD103+ DCs of the periphery are the equivalent to splenic
CD8+ DCs [38, 39], we wondered whether those cells also express Ppef2. Accor-
ding to the Immgen database (Fig. 3.2 C), CD103+ DCs show some expression
of Ppef2, although to a lesser extent than CD8+ DCs. Interestingly, the Immgen
data set also showed expression of Ppef2 in thymic CD11b+ DCs, which differ in
their development from cDCs of the spleen as they arise from CLPs instead of
CMPs [12]. Indeed, we observed Ppef2 promoter activity in CD8+ and CD11b+
DCs of the thymus, whereas CD11b+ DCs of sLN, lung, lamina propria, and mLN
did not show expression of Ppef2 (Fig. 4.1). Although the above mentioned close
relationship of CD103+ to CD8+, the CD103+ DCs of sLN, lung, lamina propria,
and mLN did not express Ppef2. This was not completely in accordance with the
microarray data provided by the Immgen consortium.
In conclusion, we were able to show expression of Ppef2 in CD8+ DCs of the spleen
on mRNA and protein level, whereas there was no expression in CD11b+ (with
the exception of the thymus) or CD103+ DCs. Based on the finding that Ppef2
shares promoter organization with the promoter region of CD11c [5], it is sur-
prising that CD11c+ CD11b+ DCs do not express Ppef2. Although the promoter
motif described above is sufficient to drive DC specific expression, the expression
of Ppef2 is most probably controlled on additional levels. Different methylation
status, Ppef2 specific silencer, Ppef2 targeting miRNAs, and many other pre- and
post-transcriptional modifications can explain the differential expression in DC
subpopulations.
5.2 Expression of Ppef2 is differentially regulated by innate
stimuli
Already the first work describing the presumably DC specific expression of Ppef2
revealed a downregulation of mRNA in BMDCs after stimulating the cells with
LPS [5]. To test whether other TLR ligands than LPS would also lead to Ppef2
downregulation, we stimulated BMDCs with TLR1/2, TLR3, TLR5 and TLR7/8
agonists. After incubation of BMDCs with LPS the expression was downregulated
by 85.7%, which was the strongest downregulation observed (Fig. 4.2 A). TLR5
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(Flagellin) and TLR3 (Poly(I:C)) stimulation led to a statistically significant
decrease in Ppef2 expression of 41.2 to 45.1% compared to a unstimulated BMDC
control. Stainings for DC maturation with the costimulatory molecule CD86
and MHCII revealed that of all TLR stimuli used in this study, the TLR5 and
TLR3 stimuli were the weakest. Still clearly leading to distinct DC maturation,
those stimuli led to about 50% fully matured DCs, whereas all other TLR stimuli
showed about 70% of fully matured DCs (data not shown). BMDC stimulation
with TLR2/TLR1 (Pam3CSK4) and TLR7/TLR8 (CL097) agonists again showed
a downregulation of Ppef2 expression and an extent of phenotypical maturation
comparable to stimulation with LPS. The extent of Ppef2 downregulation thus
correlated with the amount of fully matured DCs in culture.
Another common tool to stimulate DCs in vitro and in vivo is ligation of CD40,
a member of the TNF-receptor superfamily. Stimulation with anti-CD40 leads
to signaling via TRAFs (TNF receptor-associated factors) [126]. In DCs TRAF6
is necessary for both, LPS- and CD40-mediated signaling [127]. Schematic TLR
and CD40 signaling pathways are shown in Figure 5.1. For myeloid differentiation
primary-response protein 88 (MYD88) dependent signaling of TLRs TRAF6
can signal via different pathways, leading e.g. to activation of the transcription
factors like AP1, cAMP response element-binding protein (CREB), or NF-κB.
The latter can also be activated by CD40 signaling involving TRAF6 [128]. CD40
and TLR signaling leading to activation of NF-κB are different, although both
utilise TRAF6. In contrast to TLR signaling, CD40 mediated TRAF6 signaling
involves TRAF2 and TRAF3, which altogether bind to the cytoplasmic tail of
CD40 and contribute independently to canonical NF-κB activation [129], whereas
TRAF6 dependent TLR signaling involves IL-1R-associated kinases (IRAKs).
NF-κB activation by CD40 signaling is only one way of signaling, but it was also
shown that CD40 signaling can result in protein kinase B (Akt) activation [130].
However, we did not observe any changes in Ppef2 expression after stimulation
with a monoclonal antibody directed against CD40. Even when the anti-CD40
antibody was combined with TNFα, also triggering the TNF-receptor superfamily,
DCs did not display any change in Ppef2 expression, although the percentage of
matured DCs was comparable to stimulation with LPS.
49
5.2 Expression of Ppef2 is differentially regulated by innate stimuli
TLR
TLR ligand
TIR
domain
CD40
CD40L
IRAK4
IRAK1 IRAK2
TRAF6
TAB2 TAB3
TAK1
IKKα
IKKβ
NF-κB
MKK3
or MKK6
MKK4
or MKK7
p38 JNK
CREB AP1
TRAF2 TRAF3
TRAF6
NIK
NF-κB CREB AP1
PI3K
Akt
TRAF6 MYD88
MAL
Figure 5.1: TLR and CD40 signaling both include TRAF6. Shown are signa-
ling pathways of TLRs and CD40. Binding of TLR ligands leads to dimerization of
their receptors which initiates signaling. In a first signaling step of TLRs, the Toll–IL-
1-resistence (TIR) domains engage the myeloid differentiation primary-response protein
88 (MYD88). This stimulates downstream signaling pathways involving IL-1R-associated
kinases (IRAKs) and the adaptor molecule TNF receptor-associated factor 6 (TRAF6),
which can lead to the activation of the mitogen-activated protein kinases (MAPKs) JUN
N-terminal kinase (JNK) and p38, or to the activation of the transcription factor NF-κB.
Signaling via CD40 also involves TRAFs, like TRAF6. Signaling of CD40 via TRAF6 can,
like TLR signaling, lead to the activation of NF-κB, or to protein kinase B (Akt) signaling
via the phosphoinositide 3-kinase (PI3K). MAL, MYD88-adaptor-like protein; CD40L,
CD40 ligand; CREB, cAMP response element-binding protein; NIK, NF-κB-inducing
kinase; IKK, inhibitor of NF-κB kinase; MKK, MAP kinase kinase; TAB, TAK1-binding
protein; TAK, TGFβ-activated kinase. Modified from [131, 130, 132].
In conclusion, TRAF6 is important for signaling of CD40 and MYD88 dependent
TLRs and triggering of both can lead to activation of NF-κB, but those are not the
only signaling pathways triggered by TRAF6. Especially for CD40 signaling it was
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shown that Akt is a downstream target and known as a candidate for the promo-
tion of survival [130]. Interestingly, it was also shown that JUN N-terminal kinase
(JNK) signaling induced by LPS results in apoptosis [133]. These data fits to the
hypothesis that CD40 signaling acts pro-survival whereas TLR signaling acts pro-
apoptotic. Considering the downregulation of Ppef2 expression after TLR stimuli,
TLR induced TRAF6 signaling might involve mitogen-activated protein kinases
that e.g. lead to the activation of p38 and the cAMP response element-binding
protein (CREB), which was shown to be a repressor of transcription [134] and
therefore could be responsible for the downregulation of Ppef2 expression as addi-
tional pro-apoptotic factor next to activation of JNK [133]. CD40 signaling on the
other hand might signal via Akt, acting pro-survival and not altering the expres-
sing of Ppef2. However, the physiological role of CD40 ligation in DC maturation
is controversial and studies showed that LPS alone is not sufficient to generate
Ag-specific CTL responses in vitro, but that CD40 ligation is [135]. To test for
synergistic or antagonistic effects of LPS and anti-CD40, we combined the two
stimuli. LPS stimulation was dominant when used in combination with anti-CD40
and resulted in a degree of Ppef2 downregulation comparable with stimulation of
LPS alone.
GM-CSF generated BMDCs lack the heterogeneity of splenic DCs and recent stu-
dies showed that bone marrow cultured in GM-CSF generates both, DCs and
macrophages, which both express CD11c and MHCII [136]. Especially CD8 is a
marker that is missing on GM-CSF BMDCs. The fact that mice lacking GM-CSF
or the corresponding receptor show normal DC development in vivo [20] raises the
question of how well GM-CSF generated BMDCs resemble in vivo found DC (and
their subsets). Another method to generate mouse BMDCs in vitro is by supple-
menting bone marrow cells with Flt3 ligand [137]. Flt3L generated BMDCs show
a higher variety of DC subsets, which resemble splenic CD8+ DCs, CD11b+ DCs,
and pDCs in the surface marker expression (except the expression of CD8), the
expression pattern of TLRs and the production of cytokines [138]. Especially the
BMDCs resembling CD8+ DCs in such a culture were shown to be able to cross-
present exogenous antigens to CD8+ T cells and were developmental dependent
on IRF8 [138], which corresponds to in vivo found CD8+ DCs. For this reason,
we also evaluated in Flt3L generated BMDCs whether stimulation would lead to
downregulation of Ppef2 expression, which was the case for all the TLR ligands
tested (Fig. 4.2 B). In accordance with the GM-CSF BMDCs, stimulation of the
Flt3L BMDCs with anti-CD40 did not alter the expression of Ppef2. We analyzed
Ppef2 expression in the whole bone marrow culture, which does not allow con-
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clusions on different subpopulations which normally come up in Flt3L cultures.
Still some conclusions of Ppef2 expression in Flt3L BMDC subpopulations can
be drawn from these results. Taking the extent of Ppef2 downregulation after ad-
dition of LPS to Flt3L BMDCs argues that the pDCs present in this culture do
not express Ppef2, otherwise there should be Ppef2 expression left, since pDCs in
such a culture do not express the TLR responsible for recognizing LPS [138]. The
TLR triggered by Poly(I:C), TLR3, on the other hand, is only expressed by the
splenic CD8+ DCs and their Flt3L BMDC counterparts [138]. Also in this case,
Ppef2 expression is downregulated to a level similar to LPS treated Flt3L BMDCs.
Since the Flt3L BMDC culture is largely composed of CD11b+ DCs, expression in
this latter subtype within the Flt3L BMDC culture is unlikely. However, we can
not rule out that cytokines or other inflammatory molecules secreted or produced
by matured subpopulations within this culture influence the other subpopulations
and led to their maturation.
To evaluate the downregulation of Ppef2 expression in a more physiological setting,
we took advantage of the lacZ reporter and looked for β-galactosidase abundance
after LPS administration in vivo (Fig. 4.2 C). Administration of LPS decreased the
quantity of β-galactosidase already after 4h. Considering β-galactosidase protein
stability and turnover rate, expression of Ppef2 expression has to be downregu-
lated quickly after DC maturation. After ∼16h the β-galactosidase activity was
decreased by 86.99%. This reduction is remarkably close to the downregulation
of Ppef2 seen by qPCR (Fig. 4.2 A). The strong correlation between qPCR data
and lacZ expression, while relying on different methods and quantifying different
products, mRNA and protein, respectively, argues in favor of a linear and specific
correlation between lacZ activity and Ppef2 expression.
Spontaneous maturation, observed and described mostly in in vitro systems, is an
alternative way of DC maturation. Factors shown to contribute to spontaneous ma-
turation include adhesion molecules like E-cadherin and integrins [112, 139, 140],
soluble factors [141], as well as integrin mediated cell-cell contact not mediated
by β-catenin but Swap-70 and RhoA [142]. To check whether the spontaneous
maturation occurring in a GM-CSF BMDC culture could also lead to downregu-
lation of Ppef2 expression, we sorted CD11c+ BMDCs according to their surface
expression of MHCII and CD86 and performed qPCR analyses (Fig. 4.2 D). Com-
pletely immature DCs, identified as CD11c+ MHCIIlow CD86low, expressed Ppef2,
although it is questionable whether these cells are truly related to fully differen-
tiated DCs because of their low expression of MHCII. Interestingly, DC precursors
of the spleen do not display Ppef2 expression (Fig. 4.13 E) and Ppef2 expression
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increases during DC differentiation, as shown by analyses in a GM-CSF BMDC
culture over time with little to no expression in early stages of the culture [5]. No-
netheless, the expression decreases by half when the cells increase surface MHCII
expression to MHCIIint. Spontaneous maturation, leading to CD11c+ MHCIIhigh
CD86high DCs, further decreases the expression of Ppef2. Following the argument
that only CD11c+ MHCIIint DCs would reflect fully differentiated immature DCs,
the expression still decreases in fully matured MHCIIhigh CD86high DCs by 70.83%
(p-value=0.0122) compared to the latter. In conclusion, we observed a downregula-
tion of Ppef2 expression after spontaneous maturation that parallels the expression
profile of the whole unsorted culture stimulated with LPS. Indeed, other indepen-
dent studies have shown similarities between LPS activated and spontaneously
activated cells when looking at microarray data of e.g. miRNAS [143].
Taken together, we observed that the maturation status of DCs strongly correla-
tes with the expression of Ppef2. Expression decreased when DCs were matured
with TLR ligands or underwent spontaneous maturation. DC maturation with
anti-CD40 monoclonal antibody (even combined with TNFα), on the other hand,
did not alter the expression of Ppef2. Anti-CD40 mediated DC maturation is not
fully understood. Several studies showed that CD40 ligation is able to fully mature
DCs only in combination with a TLR stimulus [135, 144, 145]. This combination
led to downregulation of Ppef2 expression.
The maturation of DCs is a complex process that leads to numerous changes in
cellular morphology, physiology and phenotype, with several factors controlling
the process on several levels. Studies have shown that the majority of changes in
gene expression during maturation are reductions of expression [146]. Therefore,
it is difficult to conclude whether the expression profile of Ppef2 is simply a conse-
quence of co-downregulation with hundreds other genes, which are dispensable for
mature DCs, or whether it is a specific regulation due to a functionally relevant
role of the protein in the maturation of DCs.
5.3 The Ppef2 gene trap leads to loss of Ppef2
We generated Ppef2−/− mice to further investigate the role of this phosphatase in
the context of DC biology. The knockout-first approach used for this is described
in more detail in chapter 3.4.
To exclude differential splicing or short/modified transcript versions we performed
qPCRs with amplified fragments upstream and downstream of the inserted cas-
sette. mRNA downstream of the cassette was gone completely whereas the mRNA
upstream of the gene trap was reduced by over 55%.
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This remaining truncated and non-functional version of the transcript should un-
dergo nonsense mediated mRNA decay (NMD) caused by premature stop codons.
The rate or speed of NMD, as well as the expression rate of Ppef2, determine
the abundance of mRNA upstream of the gene trap. The finding that upstream
mRNA is reduced by half, instead of being completely abrogated, could argue
for constitutive expression at higher rates in immature DCs, but this would need
further investigation of mRNA turnover rates, speed of NMD and other factors
influencing RNA stability and integrity. Another important finding is that mRNA
downstream of the gene trap is completely absent. Expression of the neomycin
resistance gene located after the lacZ reporter gene and the premature stop codon
is driven by an autonomous promoter and also terminated by a polyadenylation
signal. If this stop codon, terminating the expression of the neomycin resistance,
was leaky or not functional, it could lead to expression of a transcript including
exon 5, which would correspond to the catalytic domain of Ppef2. This was not
the case in our Ppef2−/− mice.
5.4 Ppef2 controls apoptosis of DCs
The only functional study of Ppef2 published so far investigated its role in oxidati-
ve stress in COS-7 and HEK 293 A cells [97]. Ppef2 was shown to be anti-apoptotic
by a mechanism involving H2O2-induced suppression of Ask1.
Cytokine withdrawal in a GM-CSF BMDC culture is a commonly used method
to test for the susceptibility of DCs to apoptosis. GM-CSF withdrawal at a stage
where precursors already differentiated in DCs (Fig. 4.9 A) leads to apoptosis by
mechanisms involving Bim [86], PI3K/mTOR [147], and Jak3 [148].
Ppef2−/− DCs were more sensitive to apoptosis after GM-CSF withdrawal com-
pared to Ppef2+/+ DCs. There are two possible explanations for the difference
observed between Ppef2+/+ and Ppef2−/− cells during the interim expansion. Eit-
her Ppef2−/− DCs have a reduced proliferation capacity (1), or deficiency of Ppef2
leads to an increase in apoptosis (2). Since we could not observe any changes in
proliferation as measured by BrdU incorporation, but on the other hand could
detect an increase in active caspase-3, as well as phosphatidylserine, these data
suggest an increase in apoptosis (Fig. 4.9).
In summary, we observed increase in apoptosis in Ppef2−/− BMDCs after growth
factor removal. Interestingly, the interim increase in living DCs was not observed
by other groups using the same apoptosis model of cytokine withdrawal [3, 148].
The cause of this expansion of DCs could be remaining trace amounts of GM-CSF
in the culture, although cells have been washed extensively. Another reason could
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be found in the kinetics of BMDC differentiation. There still may be precursors
after 6 days of the culture that already received signals to differentiate into DCs,
or are currently undergoing differentiation, and therefore are causing the increase
in the percentage of viable DCs before induction of apoptosis takes over. However,
the increase in apoptosis after cytokine withdrawal observed in vitro led us to
question whether primary cells show the same phenotype, as GM-CSF seems to
be dispensable for DC development and maintenance in vivo [20].
To this end, we magnetically enriched CD11c+ splenocytes and kept them in cul-
ture over night with or without the supplement of GM-CSF (Fig. 4.10 A). By using
magnetically enriched CD11c+ splenocytes, different DC subpopulations and other
CD11c expressing cells were cultured together and distinguished later by flow cy-
tometry. Overall, cDCs showed a marked increase in intracellular active caspase-3
when cultured without GM-CSF (Fig. 4.10 B). Ppef2 deficiency enhanced the
apoptosis induced by the lack of GM-CSF, measurable by a reduction in the per-
centage of viable cDCs and by an increase in the amount of active caspase-3. Inte-
restingly, we observed the same effects of enhanced apoptosis in Ppef2−/− CD8+
and CD11b+ DCs (Fig. 4.10 C and D). However, the decrease in the percentage
of living cells after GM-CSF withdrawal was markedly more pronounced in CD8+
DCs (30.3% reduction) compared to CD11b+ DCs (10.9% reduction), although
both populations showed a similar increase in active caspase-3 (51.4% increase in
CD8+ DCs and 43.2% increase in CD11b+ DCs). This difference may reflect the
different turnover rates of CD8+ and CD11b+ DCs which was shown to be higher
in CD8+ DCs [52]. Nonetheless, it is puzzling why the Ppef2−/− CD11b+ DCs also
show an increase in apoptosis, lacking expression of the protein (Fig. 4.1).
Several scenarios can explain this finding: Most probably are secondary effects,
e.g. the deprivation of survival factors by dying CD8+ DCs that are important
for the maintenance of CD11b+ DCs, or the uptake of apoptotic CD8+ DCs (po-
sitive for cleaved caspase-3) by CD11b+ DCs. Also the crosstalk between CD8+
and CD11b+ DCs could provide a possible explanation. DC-DC interactions were
shown mostly between pDCs and cDCs [149, 150]; They can be mediated by solu-
ble factors like IL-15 [150], or by direct cell-cell contact, as in the case of antigen
transfer from migratory DCs to resident LN DCs [151]. With the methods used
in this study it was not possible to identify a soluble factor in the supernatant of
CD8+/+ Ppef2−/− DCs that would induce apoptosis in CD11b+ DCs.
To investigate the increase in apoptotic cells observed in vitro in a more phy-
siological setting, and without depending on exogenous cytokines (GM-CSF), we
stained primary splenocytes for active caspase-3 and surface phosphatidylserine
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(Fig. 4.11). As seen in vitro and ex vivo in the absence of GM-CSF, also in vivo
the amount of apoptotic cells was increased in the Ppef2−/− DCs. In concordance
with the turnover rate of cDC subpopulations reported in the literature [52], CD8+
DCs showed a higher caspase activity then CD11b+ DCs (Fig. 4.11 A). However,
also in vivo we observed the surprising increase of caspase activity in CD11b+ DCs
already seen when ex vivo cultured, despite the physiological absence of Ppef2 ex-
pression. Nonetheless, the enhancement of apoptosis was anyway limited to cDCs,
as none of the other cell types investigated showed any signs of increased caspase
activity (Fig. 4.11 B). Due to the exclusive expression of Ppef2 in CD8+ DCs,
the increase in apoptosis in CD11b+ is most likely caused by secondary effects.
Data from mixed bone marrow chimeras, discussed in the following sections, will
provide further evidence for this assumption.
In conclusion, we observed an increase in apoptosis in Ppef2−/− DCs in vitro and
ex vivo under suboptimal culture conditions. The same effect was observed in vivo
as shown by caspase and Annexin-V staining. The biological significance of this in-
creased apoptosis can be explained by the findings that artificially prolonged DC
longevity causes exaggerated T cell responses leading to autoimmune disorders
[1, 3, 86, 87, 88]. Ppef2 would therefore act as a molecular timer that regulates the
lifespan of DCs after their activation. This fits to our data that Ppef2 expression
decreases rapidly after maturation of DCs with TLR ligands (Fig. 4.2). Also the
finding that Ppef2 expression does not change after stimulation with anti-CD40
is in line with this hypothesis as it was shown that ligation of CD40, as well as
ligation with other members of the TNF family [2, 152], promotes DC survival
[153].
5.5 Increase in apoptosis is a CD8+ DC intrinsic effect
To evaluate whether the increase in apoptosis would lead to a disadvantage in
a competitive situation we generated mixed bone marrow chimeras (Fig. 4.12).
Analysis of the distribution of congenic markers in CD8+ and CD11b+ DCs re-
vealed that Ppef2−/− CD8+ DC had a competitive disadvantage over Ppef2+/+
CD8+ DCs. This did not hold true for CD11b+ DCs, where DCs of Ppef2+/+ or
Ppef2−/− origin were distributed equally.
This exclusivity of the competitive disadvantage observed for CD8+ but not
CD11b+ DCs strengthens the hypothesis that the enhanced apoptosis in CD11b+
DCs is a secondary effect and that Ppef2 deficiency directly influences only the
survival and competitiveness of CD8+ DCs.
In conclusion, we were able to demonstrate a role of Ppef2 in keeping the cellular
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fitness and survival of CD8+ DCs intact and that loss of Ppef2 led intrinsically to
a competitive disadvantage of Ppef2−/− CD8+ DCs, mediated through an increase
of apoptosis. However, CD11b+ DCs were not influenced by the loss of Ppef2 in the
competitive situation of mixed bone marrow chimeras, which argues for extrinsic
signals causing enhanced apoptosis in CD11c+ CD11b+ DCs. Possible extrinsic
signals, like soluble factors [150] or cell-cell contacts, are discussed in more detail
in section 5.4.
5.6 Analyses of DC proliferation and DC precursors do not
show compensatory effects
The effect of enhanced apoptosis described before did not match with the identi-
cal cell numbers of DCs observed in several organs (see chaper 4.3). Therefore, we
investigated changes in DC proliferation (and turnover), which could compensate
the loss of DCs by enhanced cell death and cause equal cell numbers.
For BrdU labeling experiments we observed inconsistent results between different
experiments. In one experiment Ppef2−/− DCs seemed to incorporate more BrdU
in the “pulse phase”, indicating an increase in proliferation, whereas in another
experiment Ppef2 deficiency led to a decrease in the BrdU+ DCs in the “chase
phase”, suggesting a faster DC turnover. However, pooling data from individual-
ly performed experiments did not result in significant differences when it comes
to DC proliferation or turnover. The same holds true for short time BrdU labe-
ling experiments (Fig. 4.13 B). Also here pooling data from three independently
performed experiments did not mark any significant differences, although some
experiments indicated an increase in proliferation.
It was shown that DC-depleted mice, or mice with reduced cDCs numbers, have
elevated serum Flt3L levels due to the decrease of cells consuming it [116, 117].
To check whether increased apoptosis would translate to an increase in the serum
level of Flt3 ligand or its receptor we performed ELISAs of the serum, as well
as flow cytometric stainings. Serum Flt3L showed only a small, non-statistically
significant (p=0.0735) tendency to be elevated (Fig. 4.13). Staining of the receptor
Flt3 revealed only minor, negligible difference of surface expression on CD11b+
DCs (Fig. 4.13 D), and no differences in DC precursors (Fig. 4.13 E).
The mice generated by the group of Steffen Jung, where DCs are depleted by
expression of diphtheria toxin A (DTA) when crossed to CD11c-Cre mice [116],
deplete DCs after promoter activity of CD11c, which is already in the pre-DC
state. On the other hand, Ppef2−/− mice show increased apoptosis in the state
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of differentiated DCs but no impact on pre-DCs. Therefore, the mice of Steffen
Jung influence the consumer of Flt3L on an earlier stage than Ppef2-deficiency
does and DC-precursors of Ppef2−/− mice still differentiate into DCs and there-
fore consume Flt3L. That might be a reason why we can not observe increased
serum levels of Flt3L to an extent comparable to CD11c:DTA mice, as increased
Flt3L is rapidly consumed by DCs or their precursors in Ppef2−/− mice but not
in the mice of Steffen Jung. Another factor influencing DC growth and survival is
lymphotoxin (LT)-β, which mainly acts on CD11b+ DCs but not on CD8+ DCs
[72, 80]. However, we did not test for increased LT-β in the serum of Ppef2−/−
mice because of its exclusive effect on CD11b+ DCs.
In conclusion, we did not observe any alterations of BrdU+ DCs in the “pulse” or
“chase” phase. Even short time BrdU labeling did not show any differences bet-
ween Ppef2+/+ and Ppef2−/− DCs. Only a small amount of in situ DCs is in cell
cycle at any given time (ca. 5%) [72] and therefore the slight tendency of increased
BrdU+ DCs after short time labeling (Fig. 4.13 B) is unlikely to compensate for
the increase in apoptosis. Effects on DC precursors might be more probable and we
consequently checked for levels of Flt3L in the serum and the surface expression of
its receptor, Flt3. Both were not markedly altered on fully differentiated DCs, as
well as on DCs precursors. The frequencies of the DC precursors themselves were
also not changed and a direct effect of Ppef2 on DC precursors can be excluded as
they do not express the protein (Fig. 4.13 E and F). With the methods available it
was not possible to detect an increase in proliferation that would compensate the
enhanced apoptosis and restore normal DC numbers. BrdU might be the wrong
choice as the DCs themselves are not highly proliferative and the immediate pre-
cursors of the spleen also show only little proliferation capacity [154]. Additionally,
investigation of one organ does take migratory precursors in consideration and the
relation between precursors and differentiated DCs is complex to determine. Also
the serum levels of Flt3L are hard to interpret and complex since it was shown
that they might be regulated by feedback loops, as inhibition of Flt3L with an
antibody results in increased serum Flt3L [77].
5.7 Ppef2 controls the ability of DCs to transiently activate
T cells in vivo
It was previously shown that changes in the lifespan of DCs influence the control of
immunity and tolerance [1, 2, 3, 4]. Most studies artificially increased the lifespan
of DCs to investigate the influence of DC longevity on immunity and tolerance.
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Here we wanted to verify whether an impaired survival of CD8+ DCs would lead
to impaired transient T cell activation.
Transient CD8+ T cell activation with OVA-pulsed DCs showed a dependency
of Ppef2, since transfer of SIINFEKL-pulsed Ppef2−/− DCs resulted in a dimi-
nished T cell proliferation, observable by reduced numbers and frequencies of
OVA-specific T cells. Signals important for the differentiation of naive T cells
into effector cells include the triggering of the T cell receptor by MHCI-associated
peptides on DCs (signal 1), costimulatory signals like e.g. triggering of CD28 on
T cells by CD80 on DCs (signal 2) and the secretion of cytokines such as IL-12 by
DCs (signal 3) (reviewed in [155, 156]). However, it has been suggested that DCs
that are in an immature state, missing signal 2 and 3, induce tolerogenic T cells.
Pulsing with peptide like performed here leads to immature DCs inducing toleran-
ce [157, 158]. Therefore signal 2 and signal 3 do not play any role in the transfer
of peptide-pulsed DCs like performed in this study. Because of the exaggerated T
cell responses in systems with artificially increased DC lifespans [1, 3, 86, 87, 88]
we hypothesize that the increased apoptosis of cDCs in Ppef2−/− mice leads to
reduced numbers of DCs that are able to induce T proliferation.
In vivo expansion of DCs for peptide-pulsing was achieved by subcutaneous im-
plantation of a Flt3L expressing tumor cell line. This leads to an increase of both
CD8+ and CD11b+ DCs, since both populations are affected by Flt3L [159], alt-
hough CD11b+ DCs to a lesser extent then CD8+ if Flt3 or Flt3L is missing
[159, 74]. However, pulsing with peptide leads to presentation of the peptide-
MHCI complex on both cDC subpopulations, but only the CD8+ DCs are able
to efficiently prime CD8+ T cells [42]. To circumvent the influence of CD11b+
DCs, we injected full OVA protein instead of pulsing with the peptide. Cross-
presentation of extracellular antigens with MHCI to CD8+ T cells is a unique
feature of CD8+ (and CD103+) DCs [42, 57, 59]. Cross-priming of OT-I cells
was impaired in Ppef2−/− mice (Fig. 4.14 A and B). The half-life of CD8+ DCs
is approximetly 1.5 days [52], and is shortened in case of Ppef2 deficiency. This
shortened lifespan of (CD8+) DCs directly influences the transient activation and
proliferation of CD8+ T cells.
In conclusion, we find an impaired transient T cell activation linked to Ppef2 defi-
ciency. This attenuated T cell proliferation was caused by an increased apoptosis
of (CD8+) DCs.
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5.8 Reduced expression of Trim2 leads to accumulation of
pro-apoptotic Bim
Dephosphorylation of the pro-apoptotic kinase Ask1 was one of the few published
specific targets for Ppef2 [97], which led us, in the first place, to the investiga-
tion of apoptosis in Ppef2−/− DCs. Nevertheless, western blot analyses of DCs
lacking Ppef2 revealed no changes in the phosphorylation status of Ask1 (data
not shown).
To find other mechanisms by which Ppef2 might drive apoptosis we performed
mRNA sequencing of sorted CD8+ and CD11b+ DCs of the spleen (Fig. 4.15).
Among the genes differentially expressed in Ppef2−/− CD8+ DCs, Trim2 and Dll4
caught our interest (Fig. 4.15 C). Both mRNAs were reduced in Ppef2−/− CD8+
DCs, which we were able to verify by qPCR (Fig. 4.15 E and F). None of the genes
differentially expressed in CD11b+ DCs lacking Ppef2 showed any connection to
apoptosis or proliferation.
Dll4 is known to be a ligand for Notch receptors [121] and Notch signaling was
shown to be important for the survival and homeostasis of CD11b+ DCs [29].
The interaction of Dll4 with its receptor can function in cis and in trans whereat
Notch is trans-activated and cis-inhibited [160, 161, 162]. Decreases in Dll4 on
CD8+ would lead to impaired Notch signaling in trans. In case of DC-DC inter-
actions, as discussed in chapter 5.4, this could lead to effects similar to the ones
observed when Notch-RBP-J signaling is knocked out by a CD11c specific Cre re-
combinase, leading to a breakdown of CD11b+ homeostasis [29]. The limited effect
on CD11b+ DCs together with the postulated cis-inhibition of CD8+ DCs makes
it contradictory that Dll4 should influence survival of CD8+ DCs. Nonetheless, we
investigated alterations in surface expression of Dll4 on DCs, and did not observe
any changes between Ppef2−/− and Ppef2+/+ DCs (Fig. 4.16 D).
Trim2, an E3 Ligase, was shown to bind the Bcl-2-interacting Mediator of Cell
Death (Bim) [120], which is an apoptotic activator [123]. Interaction of Trim2
with Bim leads to ubiquitination and proteasomal degradation of Bim [120]. Early
reports, taking advantage of a mouse strain deficient in Bim, revealed an accumula-
tion of lymphoid and myeloid cells, which led to autoimmunity and the conclusion
that Bim is necessary for homeostasis of hematopoietic cells, as well as for the con-
trol of autoimmunity [163]. Maturation of DCs by TLR ligands was later shown
to upregulate Bim and a DC specific Bim deficiency resulted in a decrease of cell
death, overactivation of lymphocytes, and autoimmunity [86].
To investigate apoptosis pathways involving Trim2 and Bim we performed wes-
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tern blot analyses of Bim in BMDCs that were either stimulated with LPS or
left unstimulated (Fig. 4.16 A & B). Bim has three isoforms, BimEL, BimL, and
BimS [123]. All three isoforms are pro-apoptotic, with BimS being the most cyto-
toxic and only transiently expressed during apoptosis. Ppef2−/− BMDCs showed
an increase in all three isoforms that was comparable to the increase after LPS
stimulus in Ppef2+/+ BMDCs (Fig. 4.16 A & B). Also Ppef2−/− spleen DCs sho-
wed an increase in pro-apoptotic Bim (Fig. 4.16 C & D). Decrease in Trim2 would
therefore lead to a intracellular accumulation of Bim, that then would drive apop-
tosis. Additionally, it was also shown that GM-CSF withdrawal in BMDC cultures
increases pro-apoptotic Bim [86] and Ppef2−/− BMDCs were more prone to apop-
tosis after cytokine withdrawal (Fig. 4.9). However, the observed increase of Bim
in CD11b+ DCs argues for additional mechanisms of Bim regulation since Trim2
was not altered in the mRNA sequencing of CD11b+ DCs.
Interestingly, Bim also is a downstream target of Jnk, which is activated by Ask1
[164, 165]. It is therefore difficult to rule out that Ask1 might also play a role
in the increase in apoptosis seen in Ppef2−/− DCs, although the phosphorylation
status of Ask1 was not altered in Ppef2−/− DCs (data not shown).
In conclusion, we showed that loss of Ppef2 led to a decrease of Trim2 mRNA
which is known to influence the protein abundance of Bim. Being a regulator of
DC apoptosis, Bim would therefore be responsible for the increase in apoptosis
observed in this study.
5.9 Conclusion and Outlook
In this study, we identified Ppef2 as a crucial survival phosphatase, the presence
of which controls DC survival and its disappearance acts as a molecular timer
following DC maturation. In this model, DC maturation itself leads to downre-
gulation of Ppef2 expression. This results in accumulation of pro-apoptotic Bim
via a mechanism involving Trim2. Increase in cytoplasmic Bim eventually leads
to apoptosis, limiting the time during which an activated DC is able to prime T
cell responses. This mechanism limits antigen responses, and protects the orga-
nism from excessive immune activation that could lead to autoimmune disorders
[1, 3, 86, 87, 88].
In addition to the experiments presented in this thesis, this model could also be
tested with a system of Ppef2 overexpression. This could be achieved by lentiviral
transduction of haematopoietic stem cells and adoptive transfer, to generate bone
marrow chimeras, or by overexpression of Ppef2 in in vitro cultures (BMDCs or
Hoxb8 cells). It would then be interesting to see whether constitutively expressed
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Ppef2 protects DCs from apoptosis, and whether this can lead to autoimmunity.
Furthermore, the same experiments performed with mutated versions of Ppef2
could allow to determine the specific protein motifs that are important for the
function of Ppef2.
Another interesting question is whether Ppef2−/− mice are protected against DC-
mediated autoimmunity, with their limited ability to induce tolerance. This can
be evaluated by crossing Ppef2−/− mice with spontaneous autoimmune models,
whereas the diminished T cell priming ability of Ppef2−/− DCs might hold the
balance with the reduced induction of tolerance.
It would also be interesting to determine the direct substrates of Ppef2, by
means of phosphoproteomics of Ppef2+/+ and Ppef2−/− mice. Combining co-
immunoprecipitation with a proteomic screening could also allow to identify the
proteins that directly interact with Ppef2, still unknown.
The CD8+ DC specific expression of Ppef2 could be used as a tool, e.g. to generate
mouse models with highly specific CD8+ DC expression of transgenes. Especially
considering the maturation dependent promoter activity, this could be used to
achieve not only cell specific expression, but also maturation dependent expressi-
on.
In the human, Ppef2 does not show an expression pattern similar to the one
observed in mice [100]. Expression of human Ppef2 is limited to the retina. The-
refore Ppef2 might not play a role in the human, although its sequence is highly
conserved. However, the family of protein phosphatases is quite large and Ppef2
orthologues, like PPP3CC, which is expressed in BDCA4+ DCs, might play a role
in human DCs. It might thus be interesting to investigate the role of this or other
phosphatases of the same family in human DC biology. Especially because Ppef2
was identified as a survival phosphatase in human cells in a screening utilizing
RNA interference (RNAi) [166].
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6.1 Materials
6.1.1 Devices
Analytic scale Adventurer, Ohaus Corp., Pine Brooks, NJ, USA
automatic pipettors Integra Biosciences, Baar, Switzerland
bench centrifuge Centrifuge 5415 D, Eppendorf, Hamburg, Germa-
ny
cell counter CASY cell counter and analyzer, OMNI life
science, Bremen, Germany
centrifuge Rotixa RP, Hettich, Tuttlingen, Germany
chemical scale Kern, Albstadt, Germany
ELISA-reader νmax kinetic mircroplate reader, Molecular Devi-
ces, Biberach, Germany
flow cytometer FACSCalibur, FACSCantoII and FACSAria, BD
incubator Hera cell, Heraeus Kendro Laboratory Products,
Hanau, Germany
irradiator Gammacell 40, AECl, Mississauga, Canada
laminar airflow cabinet Heraeus
magnetic stirrer Ika Labortechnik, Staufen, Germany
PCR-machine Biometra, Goettingen, Germany
pH-meter Inolab, Weilheim, Germany
pipettes Gilson, Middleton, WI, USA
power supply Amersham Pharmacia, Piscataway, NJ, USA
real-time PCR machine CFX96 Real Time System, BIO-RAD, Hercules,
CA, USA
vacuum pump KNF Neuberger, Munzingen, Germany
vortex-Genie2 Scientific Industries, Bohemia, NY, USA
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water bath Grant Instruments Ltd., Barrington Cambridge,
UK
6.1.2 Consumables
Disposable syringe filter (0.2 + 0.45
µm)
Nalgene Nunc Int., Rochester, NJ, USA
Disposable injection needle (26 G x
1/2”)
Terumo Medical Corporation, Tokyo,
Japan
Disposable syringe (1+5 ml) Reacti-
on
Braun, Melsungen, Germany
reaction container 5 ml (FACS) BD, Franklin Lakes, NJ, USA
reaction container 15 ml and 50 ml Greiner, Frickenhausen, Deutschland
BD Microtainer BD, Franklin Lakes, NJ, USA
DuoSet mFlt3L ELISA R&D Systems, MN, USA
6.1.3 Chemicals
Unless stated otherwise, chemicals were purchased from Merck (Darmstadt, Ger-
many), Roth (Karlsruhe, Germany) or Sigma-Aldrich (St. Louis, MO, USA). All
buffers and solutions were prepared using double distilled water.
6.1.4 Buffer and media
ACK: 8.29 g NH4Cl
1 g KHCO3
37.2 mg Na2EDTA
H2O ad 1 L
pH 7.4
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CFSE-staining buffer: PBS
0.03% FCS
Cresol red buffer: 250 mM KCl
50 mM Tris-HCl (pH 8.3)
43% Glycerol
2 mM Cresol red
7.5 mM MgCl2
FACS buffer: PBS
2% FCS
0.01% NaN3
Flt3L medium: RPMI 1640
10% FCS
500 mM β-mercaptoethanol
100 U/ml Penicillin
100 g/ml Streptomycin
5 ml Glutamin
200 ng/ml Flt3L
GM-CSF medium: IMDM
10% FCS
500 mM β-mercaptoethanol
100 U/ml Penicillin
100 g/ml Streptomycin
5 ml Glutamin
10 ml GM-CSF
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HBSS: 137 mM NaCl
5.4 mM KCl
0.25 mM Na2HPO4
0.1 g glucose
0.44 mM KH2PO4
1.3 mM CaCl2
1.0 mM MgSO4
4.2 mM NaHCO3
HBSS-EDTA: HBSS
8% FCS
10 mM EDTA
10 mM HEPES
PBS: 137 mM NaCl
2.7 mM KCl
10 mM Na2HPO4
pH 7.4
50x TAE buffer: 242 g Tris-HCl
57.1 ml 100% acetic acid (v/v)
100 ml 0.5 M EDTA (pH 8.0)
H20 ad 1 L
10x Gitocher: 670 mM Tris pH 8.8
166 mM NH
65 mM MgCl2
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0.1% gelatin
1x Gitocher buffer: 5 µl 10x Gitocher buffer
2.5 µl 10% Triton X-100 (v/v)
0.5µl β-mecaptoethanol
3 µl proteinase K (10 mg/ml)
39 µl H2O
6.1.5 Antibodies
Antibodies and fluorochrome linked Streptavidin used for flow cytometry:
epitope conjugate clone manufacturer
B220 Pacific Blue RA3-6B2 eBioscience
PE RA3-6B2 BD
PerCP RA3-6B2 BioLegend
Bim unlabeled C34C5 Cell Signaling
BrdU FITC BD
CD3 biotin 145-2C11 BD
FITC 145-2C11 eBioscience
PE 145-2C11 eBioscience
PerCP 145-2C11 BD
CD4 APC RM4-5 eBioscience
FITC H129.19 BD
PE GK1.5 BD
Pe-Cy7 GK1.5 eBioscience
PerCP RM4-5 BD
CD5 bio 53-7.3 BD
CD8 APC 53-6.7 eBioscience
APC-Cy7 53-6.7 eBioscience
Continued on the next page.
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epitope conjugate clone manufacturer
BV 53-6.7 BioLegend
PE 53-6.7 BD
PeCy7 53-6.7 eBioscience
CD9 FITC MZ3 BioLegend
CD11b APC-eFlour780 M1/70 eBioscience
CD11c APC N418 eBioscience
PB N418 eBioscience
PeCy7 N418 BioLegend
CD16/32 unlabeled 2.4G2 BD
CD19 APC 1D3 BD
biotin 1D3 BD
PE 1D3 BD
Pe-Cy7 1D3 BD
PerCP 1D3 BD
CD21/35 PE 7G6 BD
CD23 APC B3B4 BioLegend
CD24 APC M1/69 BioLegend
CD40 APC 1C10 eBioscience
CD43 Biotin S7 BD
FITC S7 BD
CD44 PE IM7 eBioscience
CD45 Brilliant Violet 30-F11 BioLegend
PE 30-F11 eBioscience
PerCP 30-F11 BD
CD45.1 APC A20 eBioscience
bio A20 BD
FITC A20 eBioscience
Continued on the next page.
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epitope conjugate clone manufacturer
Pacific Blue A20 BioLegend
PE A20 eBioscience
CD45.2 FITC 104 BioLegend
APC 104 BioLegend
CD62L APC MEL-14 BD
CD64 APC X54-5/7.1 BioLegend
CD69 PE H1.2F3 BD
CD86 PE GL-1 eBioscience
PerCP GL-1 BioLegend
CD90.1 PerCP OX-7 BD
CD103 Brilliant Violet M290 BD Horizon
PE M290 BD
CD115 APC AFS98 eBioscience
PeCy7 AFS98 eBioscience
CD135 PE A2F10 eBioscience
CD161c PE PK136 BD
CD172a APC P84 BD
cl. Casp. 3 FITC C92-605 BD
unlabeled D3E9 Cell Signaling
Dll4 PE HMD4-1 BioLegend
EpCam
(CD326)
APC G8.8 BioLegend
ESAM PE 1G8 eBioscience
F4/80 PE BM8 eBioscience
PeCy7 BM8 eBioscience
Fas FITC Jo2 Pharmingen
GL-7 PB GL-7 eBioscience
Continued on the next page.
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epitope conjugate clone manufacturer
goat a-rabbit PE Life Technologies
Gr1 PE RB6-8C5 BD
IgD PB 11-26 eBioscience
PE 11-26c.2a BioLegend
IgM PeCy7 II/41 eBioscience
IL-12 (p40/p70) PE C15.6 BD Pharmingen
KI67 PE B56 BD Pharmingen
LAMP-1 PeCy7 1D48 BioLegend
Langerin FITC 929F3.01 Dendritics
Ly6C FITC AL-21 BD
Ly6G BV 1A8 BioLegend
APC 1A8 BD
MHCII APC M5/114.15.2 eBioscience
FITC M5/114.15.2 BioLegend
PE M5/114.15.2 eBioscience
PerCP M5/114.15.2 BioLegend
PDC-TREM PE 4A6 BioLegend
PDCA-I APC 129c1 BioLegend
Siglec-H APC 551 BioLegend
FITC 551 BioLegend
PerCP 551 BioLegend
Streptavidin APC-Cy7 CALTAG
PB BioLegend
PeCy7 eBioscience
PerCP BD
V-a2 APC B20.1 eBioscience
V-b5 PE MR9-4 BD
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Antibodies used for Western-Blot analyses:
epitope clone isotype manufacturer
Bim C43C5 Rabbit IgG Cell Signaling
GAPDH 14C10 Rabbit IgG Cell Signaling
Anti-rabbit, HRP conjugated antibodies were purchased from Jackson Immuno-
Research Laboratories (West Grove, PA, USA).
6.1.6 Oligonucleotides, peptides and proteins
All oligonucleotides were purchased at MWG-Biotech AG (Ebersberg, Germany).
Ovalbumin protein grade VII was bought from Sigma-Aldrich (St. Louis, MO,
USA).
target primer name sequence probe
Ppef2 Ppef2_ex._11_fw TTCTGTCACAACCGCAAGG 16
Ppef2_ex._12_rv TCTGTTGCTGCCAACTTCAT
Ppef2 Ppef2_ex._2_fv AGGAGGCGATGTACCTGGA 56
Ppef2_ex._3_rw CAAGGTAGCTGAAGAATTC-
ATGG
Ppef2 Ppef2_ex._4_fv CTTCCTGACCATGCCACTG 31
Ppef2_ex._5_rw TATCGAGCATGGAGCTGT-
TG
CD11c CD11c_fw CCAGTTGGAGCTTCCAGT-
AAA
46
CD11c_rv CCTTTTCTGAGGTTGAGA-
AGTTAAG
Continued on the next page.
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target primer name sequence probe
Trim2 Trim2_fw TTTCCATAATCACTCTGTC-
AAGGT
12
Trim2_rv CCATTGGAGCCAAACTTCA
Dll4 Dll4_fw AGGTGCCACTTCGGTTACAC 106
Dll4_rv GGGAGAGCAAATGGCTGATA
HPRT HPRT_fw TCCTCCTCAGACCGCTTTT 95
HPRT_rv CCTGGTTCATCATCGCTAA-
TC
Frt site 5’ FRT_fw AGGCGCATAACGATACCACGAT
5’ FRT_rv CCACAACGGGTTCTTCTGTT
Ppef2 Ppef2_WT_fw TAGTGCTCGCCAAGTTGAGA
Ppef2_WT_rv TAACCCCTACCCCTCTGCTT
6.1.7 Mouse strains
All mice except the H2-Kbm1 mice were bred and kept in the Institute for
Immunology at the LMU Munich. H2-Kbm1 mice were bred and kept in the
Institut für Medizinische Mikrobiologie, Immunologie und Hygiene at the TU
munich, where the experiments with those animals were conducted.
C57BL/6
C57BL/6 mice were in-house bred as inbred line for several generations in the
Institute for Immunology at the LMU Munich. Mice are Ppef2+/+ and were used
for breedings and as controls for Ppef2−/− mice.
Ly5.1
Ly5.1 mice express the Ly5.1 allele which serves as congenic marker and were
kept on a C57BL/6 background.
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Ppef2−/−
Alleles targeting Protein phosphatase with EF-hands 2 (Ppef2) and leading to
a complete knockout were produced for the EUCOMM and EUCOMMTools
projects by Wellcome Trust Sanger Institute (WTSI) [102]. Embryonic stem
cells were purchased at EUCOMM and microinjection in C57BL/6 oocytes was
performed by the Transgenic Core Facility at the MPI of Molecular Cell Biology
and Genetics in Dresden. Chimeric mice were further crossed with C57BL/6 mice.
OT-I
This mouse strain carries a transgenic T cell receptor specific for the ovalbumin-
derived peptide SIINFEKL that is presented to CD8+ T cells in the context
of H2-Kb [167]. The T cell receptor of these mice uses the Vβ2 and the Vβ5
segments and T cells can be visualized using mAb directed against these two
segments. For identification of OT-I cells in transfer experiments animals were
either crossed to the congenic CD45.1 or CD90.1 strain.
H2-Kbm1
The bm1 mutation of the H2-Kb gene contains 7 nucleotide differences resulting in
amino acid substitutions at codon 152 (glutamate to alanine), codon 155 (arginine
to tyrosine) and codon 156 (leucine to tyrosine). This results in a failure to present
the OVA peptide SIINFEKL via MHCI [119].
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6.2 Methods
6.2.1 Immunological and cell biology methods
6.2.1.1 Generation of BMDCs
BMDCs were either generated by addition of GM-CSF, or by addition of Flt3L
to bone marrow cells. In both cases bone marrow was isolated as described in
“Harvesting of blood and organs and single cell preparation” on page 74.
For GM-CSF BMDC cultures 107 cells were plated in 10 ml of GM-CSF containing
medium (20 ng/ml GM-CSF) in a 100 mm plate and cultured under 37 ◦C and
5% CO2 conditions. At day 3 of the culture, cells were harvested with Trypsin,
counted, and again plated at a density of 5·106 cells in a 10 mm plate in 10 ml of
GM-CSF medium. For analysis, cells were harvested at day 8 of the culture with
cold PBS.
For Flt3L cultures 3·106 bone marrow cells were cultured with 2 ml Flt3L medium
per well of a non-surface-treated 24 well plate. For analysis of Flt3L generated
DCs, cells were harvested at day 8 with cold PBS.
Mature BMDCs were obtained by stimulation overnight with 2 µg/ml lipopoly-
saccharide (LPS, Sigma-Aldrich), 1 µg/ml Flagellin, 2.5 µg/ml Poly I:C, 1 µg/ml
Pam3CSK4, 2.5 µg/ml CLO97, or 100 µg/ml antiCD40 respectively. To obtain
higher percentages of matured BMDCs, antiCD40 stimulus (100 µg/ml) was com-
bined with either TNFα (10 ng/ml), or LPS (2 µg/ml).
6.2.1.2 Harvesting of blood and organs and single cell preparation
Animals were sacrificed either by CO2 or by cervical dislocation after they had
been sedated using Isoflurane. Organs were removed using scissors and fine
tweezers and put into phosphat buffered saline (PBS) on ice. Blood was flushed
out of lungs before by disruption of the aorta followed by injection of cold PBS
in the right ventricle. Spleen, thymus, lymph nodes and lungs were then digested
with DNAse I (0.2 mg/ml) and Liberase (0.65 Wuensch units/ml, both Roche)
for 30 min at 37 ◦C. Afterwards the organs were passed through a 100 µm
cell strainer, washed once with cold PBS and red blood cells were lysed using
ACK buffer for 2 min at room temperature. Cells were washed once again and
counted using CASY-counter (OMNI life science) and used for further analysis or
experiments.
To analyze cells of the lamina propria, colon was taken from a mouse, fecal
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content removed, the colon opened longitudinally and cut into approximately 5
mm big pieces. The pieces were then incubated with HBSS-EDTA for 10 min
on a shaker at 37 ◦C, the supernatant, containing epithelial cells, was discarded
and gut parts were washed twice with ice-cold PBS. Afterwards, the colon was
digested once for 30 min and then twice for 20 min with a mixture of Collagenase
IV (157 Wuensch units/ml, Worthington), DNAse I(0.2 mg/ml) and Liberase
(0.65 Wuensch units/ml, both Roche), the supernatant was collected after each
digestion and the cells were washed once with PBS.
Cells from all three digestions were combined and immune cells enriched using
gradient centrifugation. To this end, cells were resuspended in 40% Percoll and
this solution was overlayed onto a 80% Percoll solution. This was centrifuged
for 20 min at 1800 rpm and 4 ◦C without break. Cells at the interphase were
collected, washed once and used for further analysis.
For analysis of dermal and epidermal cells ears were removed. The dorsal and
ventral layers were separated with fine forceps and incubated dermal face down
in 2 U/ml of Dispase II (Roche) in HBSS in 24 well plate for 90 min at 37 ◦C.
Skin sheets were separated into dermis and epidermis with fine forceps in cold
PBS. Epidermal sheets were further incubated for 2 hours at 37 ◦C in HBSS with
157 U/ml of collagenase IV (Worthington) and 10% FCS in 24 well plate. Dermal
sheets were digested for 2 hours at 37 ◦C in a solution containing 0.5 mg/ml of
DNase I, 2.7 mg/ml of Collagenase XI, 27 µg/ml of Hylaronase VI and 10 mM of
Hepes in RPMI.
The suspensions were passed through a cell strainer and the sheets were mashed
on the cell strainer to obtain a homogeneous cell suspension. The cells were
washed and counted. They were then stained for flow cytometric analyses.
Isolation of liver cells was carried out by mashing the organ through a 100 µm
mesh in PBS. Afterwards, mononuclear cells were enriched by applying a gradient
using Lymphoprep (STEMCELL Technologies). Hepatocytes and other cells were
cleared out and positively enriched cell fraction was further used for counting and
stainings.
For the isolation of bone marrow the terminal parts of femurs and tibiae were
cut open and the bone marrow was flushed out with needle and syringe using
medium containing 10% FCS. Red blood cells were lysed for 2 min in ACK buffer
and the cell suspension was passed over a cell strainer to remove debris. Cells
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were subsequently subjected to cell culture, or frozen for future use in BMDC
medium supplemented with 10% extra FCS and 10% dimethyl sulfoxide (DMSO)
at −80 ◦C.
6.2.1.3 Flow Cytometry staining
For flow cytometric analysis 2·106 cells were used per staining in a FACS acquisiti-
on tube. Cells were washed once with 200 µl FACS buffer and then stained for 20
min at 4 ◦C in the dark in 100 µl of antibody mix in FACS buffer. Each antibody
has been titrated for optimal use. After the incubation cells were washed once
with 200 µl FACS buffer and either directly acquired at the FACS, or fixed for
overnight storage using FACS buffer containing 2% paraformaldehyde. Cells that
have been stained with a biotinylated mAb were stained in a second step with a
fluorescently labeled streptavidin, also in a volume of 100 µl at 4 ◦C in dark for
additional 20 min.
For intracellular stainings cell were fixed and permeabilized after they have been
stained for all extracellular markers. For the staining of cleaved caspase-3 cells
were washed once and then resuspended in 200 µl 4% PFA for 15 min at room
temperature in the dark. After washing twice with 1x fixation/permeabilisation
buffer (BD) cells were blocked for 10 min with an anti CD16/32 antibody (Fc
block) and 0.1% goat serum at 4 ◦C. After 10 min of blocking, 100 µl anti clea-
ved caspase-3 antibody was added and cells were incubated for 30 min at 4 ◦C.
Unbound antibody was washed away and cells were incubated with 100 µl fluoro-
chrome conjugated secondary antibody at 4 ◦C for 30 min. Afterwards cells were
washed once and acquired at the FACS.
Acquisition was performed using a FACSCanto II. Cell sorting was performed at
FACSAria (all BD). Data analysis was performed using FlowJo version 8 and 9
(TreeStar, Ashland, OR, USA).
Flow cytometric analyses as performed by the Centre d’Immunophénomique (CI-
PHE) were performed in two different panels to identify various cell population
with the markers listed below. Following cell populations were defined as possible
dump population for gating out:
dump populations marker
Eosinophils CD5- CD19- CD11b+ MHCII- SSChi
Neutrophils CD5- CD19- Eosino- Macro- CD11b+ Ly6Cint
Continued on the next page.
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dump populations marker
Monocytes CD11b+ Ly6G- Ly6Chi
pDC CD5- CD19- Eosino- Macro- Mono- CD11clo
CD317+ CD45R+ Ly6C+
Macrophages CD11bint Ly6G- Ly6C- F4/80hi
The following markers were used by CIPHE to define populations of the spleen in
two different staining panels:
population marker
Eosinophils (Panel 4) CD5- CD19- CD11b+ MHCII- SSChi
Infl. DCs CD5- CD19- Eosino- Macro- Mono- pDC- CD11c+
MHCII+ CD64+
Stage I (% pDC) CD5- CD19- Eosino- Macro- Mono- CD11clo
CD317+ CD45R+ Ly6C+ CD4- CD8-
gd T cells CD161- Ly6G- CD317- CD5+ CD3+ TCRd+
CD4 shedding [CD4
CD44-CD62L- (Shed-
ding)]
CD161- Ly6G- CD317- CD5+ CD3+ TCRd- CD4+
CD44- CD62L-
Eosinophils (Panel 1) CD11b+ Ly6G- Ly6Clo SSChi
CD4 Naive CD161- Ly6G- CD317- CD5+ CD3+ TCRd- CD4+
CD44- CD62L+
Cellularity -
B1 B cells CD161- Ly6G- CD317- CD19+ MHCII+ CD5+
Xcr1 cDCs CD5- CD19- Eosino- Macro- Mono- pDC- CD11c+
MHCII+ CD64- CD24+ CD172a- CD8a+
IgDlo B2 B cells CD161- Ly6G- CD317- CD19+ MHCII+ CD5- IgDlo
CD8 naive CD161- Ly6G- CD317- CD5+ CD3+ TCRd- CD8+
CD44- CD62L+
gd Naive CD161- Ly6G- CD317- CD5+ CD3+ TCRd+ CD44-
CD62L+
Continued on the next page.
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population marker
CD4- CD8+ (%pDCs) CD5- CD19- Eosino- Macro- Mono- CD11clo
CD317+ CD45R+ Ly6C+ CD4- CD8+
CD8 shedding [CD8
CD44-CD62L- (Shed-
ding)]
CD161- Ly6G- CD317- CD5+ CD3+ TCRd- CD8+
CD44- CD62L-
gd shedding [gd cd44-
cd62l- (Shedding)]
CD161- Ly6G- CD317- CD5+ CD3+ TCRd+ CD44-
CD62L-
NKT CD161+ Ly6G- CD317- CD5+
IgDhi B2 B cells CD161- Ly6G- CD317- CD19+ MHCII+ CD5- IgDhi
CD8 CD161- Ly6G- CD317- CD5+ CD3+ TCRd- CD8+
CD4 CM CD161- Ly6G- CD317- CD5+ CD3+ TCRd- CD4+
CD44+ CD62L+
NK CD11b+Ly6C+ CD161+ Ly6G- CD317- CD5- CD11b+ Ly6C+
CD4 EM CD161- Ly6G- CD317- CD5+ CD3+ TCRd- CD4+
CD44+ CD62L-
NK CD161+ Ly6G- CD317- CD5-
CD8 CM CD161- Ly6G- CD317- CD5+ CD3+ TCRd- CD8+
CD44+ CD62L+
B cells CD161- Ly6G- CD317- CD19+ MHCII+
Viability -
B2 B cells CD161- Ly6G- CD317- CD19+ MHCII+ CD5-
ab T cells CD161- Ly6G- CD317- CD5+ CD3+ TCRd-
CD4 CD161- Ly6G- CD317- CD5+ CD3+ TCRd- CD4+
CD11b+ DCs CD5- CD19- Eosino- Macro- Mono- pDC- CD11c+
MHCII+ CD64- CD24+/- CD172a+ CD11b+
Imm CD11b+ DCs CD5- CD19- Eosino- Macro- Mono- pDC- CD11c+
MHCII+ CD64- CD24+/- CD172a+ CD11b+
CD117+
Continued on the next page.
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population marker
Imm Xcr1 DCs CD5- CD19- Eosino- Macro- Mono- pDC- CD11c+
MHCIIlo CD64- CD24+ CD172a- CD8a+ CD117+
gd CM CD161- Ly6G- CD317- CD5+ CD3+ TCRd+
CD44+ CD62L+
CD11b-type DC CD11b- Ly6G- CD11b- CD317- CD11c+ MHCII+
CD11b+
NK CD11b-Ly6C+ CD161+ Ly6G- CD317- CD5- CD11b- Ly6C+
Stage III (%pDCs) CD5- CD19- Eosino- Macro- Mono- CD11clo
CD317+ CD45R+ Ly6C+ CD4+ CD8-
gd EM CD161- Ly6G- CD317- CD5+ CD3+ TCRd+
CD44+ CD62L-
Stage II (%pDC) CD5- CD19- Eosino- Macro- Mono- CD11clo
CD317+ CD45R+ Ly6C+ CD4+ CD8+
CD8 EM CD161- Ly6G- CD317- CD5+ CD3+ TCRd- CD8+
CD44+ CD62L-
Mat Xcr1 DC CD5- CD19- Eosino- Macro- Mono- pDC- CD11c+
MHCIIlo CD64- CD24+ CD172a- CD8a+ CD117-
Mat CD11b+ DC CD5- CD19- Eosino- Macro- Mono- pDC- CD11c+
MHCII+ CD64- CD24+/- CD172a+ CD11b+
CD117-
Xcr1 DC CD5- CD19- Eosino- Macro- Mono- pDC- CD11c+
MHCII+ CD64- CD24+ CD172a- CD8a+
Macrophages CD5- CD19- CD24+ CD172a+ CD64+
cDC (Panel 4) CD5- CD19- Eosino- Macro- Mono- pDC- CD11c+
MHCII+
Neutrophils (Panel 1) CD11b+ Ly6G+
Neutrophils (Panel 4) CD5- CD19- Eosino- Macro- CD11b+ Ly6Cint
Monocytes CD5- CD19- Eosino- Macro- CD11b+ Ly6C+
NK CD11b-Ly6C- CD161+ Ly6G- CD317- CD5- CD11b- Ly6C+
Continued on the next page.
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population marker
Monocytes CD11b+ Ly6G- Ly6Chi
pDC (Panel 1) CD11b- Ly6G- Ly6Chi CD317+
pDC (Panel 4) CD5- CD19- Eosino- Macro- Mono- CD11clo
CD317+ CD45R+ Ly6C+
Other Mac CD11bhi Ly6G- Ly6C- F4/80hi
RP Macrophages CD11bint Ly6G- Ly6C- F4/80hi
6.2.1.4 Measurement of β-galactosidase (lacZ) expression and activity
Measurement of the expression of the bacterial β-galactosidase gene (lacZ) was
carried out by using the FluoReporter lacZ Flow Cytometry Kit (Thermo Fisher
Scientific Inc.) according to the manufacturers protocol. Therefore the activity of
the enzyme was measured by adding Fluorescein isothiocyanate (FITC) coupled
substrate (fluorescein di-V-galactoside (FDG)) for 2 min at 37 ◦C and stopping
of the reaction by addition of cold staining medium. Followed by normal surface
antibody staining samples were analyzed using a FACSCanto II.
6.2.1.5 Enzym-linked immunosorbent assay (ELISA) for Flt3L
Blood of animals was taken by cardiac puncture after sacrificing the mice by
cervical dislocation and directly transferred into microtainer tubes (BD). After
incubation for 30 min at room temperature blood coagulated and was spun down
1.5 min at 8000 rpm. Serum was stored at −20 ◦C until use.
Serum was diluted 1:20 with PBS and ELISA was carried out according to the ma-
nufacturers protocol (DuoSet mFlt3L ELISA, R&D Systems, Minneapolis, USA).
6.2.1.6 Generation of bone marrow chimeras
To generate bone marrow chimeras, recipient mice were irradiate with two sepa-
rate doses of 550 rad using a Cesium source (Gammacell 40, AECl, Mississauga,
Canada). Irradiated animals were reconstituted with 5·106 bone marrow cells, 1:1
mixed from Ly5.1+ and Ly5.2+ bone marrow. To prevent infection, animals recei-
ved 1.2 g/l neomycin in water ad libitum for 4 weeks. Animals were analyzed 8 to
10 weeks after reconstitution.
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6.2.1.7 Magnetic cell sorting
To purify cell populations based on surface marker expression magnetic cell sorting
(MACS, Miltenyi Biotec) was employed. This technique uses antibodies reactive
to certain surface antigens and coupled to magnetic beads. After cells have been
incubated with these antibodies for the appropriate amount of time they can be
applied to a column that is placed in a paramagnetic field. Labeled cells are re-
tained on the column, while unlabeled cells are washed away. Columns are rinsed
three times and the eluted fraction can be collected.
This technique was actually employed when CD8+ T cells were purified for ad-
optive transfer experiment (CD8+ T cell Isolation Kit, negative selection), for
depletion of T and B cells before sorting of DCs (biotin conjugated antibodies
against CD3 and CD19 and anti-biotin microbeads), or for the enrichment of DCs
(CD11c microbeads). All procedures were performed according to the manufac-
turers instructions.
6.2.1.8 Adoptive T cell transfer
To transfer transgenic T cells into experimental animals spleens from transgenic
animals were taken and the respective T cells purified using a CD8 T cell enrich-
ment kit (see 6.2.1.7). Purity of the cell suspension was checked using anti-CD8
antibody in combination with an appropriate Vβ antibody specific for the respec-
tive TCR.
If not stated otherwise 0.5·106 CD8+ T cells were transferred intravenously into the
syngenic and sex-matched mice. Transferred cells could be followed by analyzing
the congenic markers CD45.1 or CD90.1.
6.2.1.9 Immunofluorescence staining
Organs were directly embedded in Tissue-Tek OCT compound (Sakura Finetek,
Zoeterwoude, The Netherlands) and snap frozen in liquid nitrogen. Sections of 5-7
µm were cut using a cryostat instrument (Leica Microsystems, Wetzlar, Germa-
ny), fixed for 20 min at −20 ◦C using aceton and subsequently dried over night in
the dark.
Before staining the slides were adjusted to room temperature and rehydrated for
15 min with PBS containing 0.25% bovine serum albumin (BSA). To minimize
unspecific binding the slides were then incubated with PBS, 0.25% BSA contai-
ning 10% mouse serum.
Staining was performed in a moist chamber in the dark for 30 min at room tem-
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perature. After staining the slides were washed and cover slides put on. The slides
were analyzed using a BX41 microscope equipped with a F-view II camera and
cellF software (all from Olympus, Hamburg, Germany).
6.2.1.10 Cytokine bead array
Blood of animals was taken via puncturing the heart, the blood was transferred
into a microtainer tube (BD, Franklin Lakes, NJ, USA) and incubated at room
temperature for 30 min, so that the blood could coagulate. Afterwards the tube
was centrifuged at 8000 rpm for 1.5 min at room temperature and the serum was
frozen at −20 ◦C until use.
To measure up to six different cytokines in the same amount of serum the BD
Cytokine Bead Array mouse inflammation kit was employed. Serum samples were
titered in the beginning to ensure an optimal concentration for the assay. The
assay procedure was then performed according to manufacturers instructions.
Acquisition of the samples was performed using a FACSCantoII. Results were
analyzed using FCAP Array Software (Soft Flow Inc.).
6.2.1.11 DC vaccination
DCs of Ppef2+/+ or Ppef2−/− mice were in vivo expanded for up to ten days
by subcutaneously injecting a Flt3L secreting tumor cell line. After in vivo ex-
pansion, DCs were magnetically purified by using a DC isolation kit (see 6.2.1.7)
and 1.5·105 SIINFEKL pulsed DCs were transferred into Kbm1 recipient mice. One
day later, recipient mice received congenitally marked (CD45+) OT-I cells intra-
venously. Three days after adoptive T cell transfer mice were analyzed for T cell
proliferation by flow cytometry. Experiments were carried out by the group of Veit
Buchholz/Dirk Busch at the Institut für Medizinische Mikrobiologie, Immunologie
und Hygiene at the TU munich.
6.2.2 Molecular biology
6.2.2.1 Gel electrophoresis
To visualize DNA fragments and to separate them according to their size they were
applied to gelelectrophoresis on an agarose gel. Gel was prepared by dissolving 0.8-
2% agarose in TAE buffer, depending of the fragment size that was supposed to be
visualized. To estimate the size of the fragments either a 100bp or a 1kb ladder was
used (New England Biolabs, Ipswich, MA, USA). PCR fragments either already
contained loading buffer or a buffer consisting of 10% glycerol and xylene cyanol
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FF was added directly before applying the sample to the gel. The DNA samples
were visualized using ethidium bromide (0.5 µg/ml) that was added to the gel
followed by examination with UV light (312 nm, Intas, Goettingen, Germany).
6.2.2.2 Isolation of genomic DNA
To isolate genomic DNA for genotyping 2-5 mm of mouse tail tip was cut, put
into 50 µl 1x Gitocher buffer, and incubated at 55 ◦C for 6h. Proteinase K was
inactivated at 95 ◦C for 5 min.
6.2.2.3 Isolation of total Ribonucleic acid (RNA)
Total RNA was isolated by resuspending a pellet of up to 107 cells in 1 ml of
Trizol. After incubation for 10 min on ice 300 µl chloroform was added and incu-
bated another 15 min on ice. Suspension was spun down 10 min at 1300 rpm in
a cooled tabletop centrifuge. The upper aqueous phase was transferred in a new
2 ml reaction tube and 2 volumes of chloroform were added on top. After cen-
trifugation for 10 min under the conditions mentioned before the aqueous phase
was transferred into a new 2 ml reaction tube. To precipitate the RNA 1 volume
of isopropanol and, for better visualization of the RNA pellet, 1 µl of Glycoblue
was added. Samples were then incubated for at least 2 h at −80 ◦C or overnight
at −20 ◦C. After centrifugation for 30 min at 1300 rpm in a cooled tabletop cen-
trifuge the supernatant was removed carefully and pellet was washed by adding
400 µl 70% ethanol followed by centrifugation for 10 min. To dry the pellet the
supernatant got poured off and and the pellet air dried. According to the expected
final RNA concentration the pellet got resuspended in an appropriate amount of
water and concentration was determined by spectrophotometry (NanoDrop 1000,
Thermo Fischer Scientific, Waltham, Massachusetts, USA).
6.2.2.4 cDNA synthesis
Equal amounts of RNA were used to generated cDNA using the QuantiTect Rever-
se Transcription Kit (Qiagen, Venlo, Netherlands) according to the manufacturers
protocol.
6.2.2.5 Polymerase Chain Reaction (PCR)
For genotyping of Ppef2 deficient mice PCRs were performed with the primers
listed in Oligonucleotides, peptides and proteins on page 71 with small amounts
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of genomic DNA isolated from tail biopsies. The reaction mix contained
Cresol red buffer with MgCl2 6 µl
forward primer (100 pmol/µl) 0.2 µl
reverse primer (100 pmol/µl) 0.2 µl
dNTPs (2.5 mM) 2 µl
PANScript DNA Polymerase (5 U/ml) 0.25 µl
H20 20.35 µl
template DNA 1 µl
PCR reactions were performed with a T3 Thermocycler (Biometra). After an
initialization step of 5 min at 94 ◦C the samples were amplified for 35 circles
beginning with an denaturation step at 94 ◦C for 30 sec followed by an annealing
step of 58 ◦C for another 30 sec and ended with extension/elongation step for 45
sec at 72 ◦C. After the 35 circles a final elongation step for 5 min at 72 ◦C was
performed and amplified fragments were stored at 4 ◦C until loading on a 1.8%
agarose gel.
6.2.2.6 qPCR
qPCRs were performed on a CFX96 Real Time System (BIO-RAD) using the
LightCycler 480 Probes Master kit (Roche) according to the manufacturers pro-
tocol. The primers and probes used are depicted in the section “Oligonucleotides,
peptides and proteins” on page 71. Expression levels were, unless stated otherwise,
normalized to HPRT and relative quantification was calculated using either the
2-∆C’t method [104, 105], or the ∆∆Ct method.
6.2.2.7 mRNA-Sequencing
Samples for mRNA-Sequencing were FACS sorted of spleens of Ppef2+/+ and
Ppef2−/− mice. Up to 106 sorted cells were resuspended in 1 ml of Trizol and snap
frozen in liquid nitrogen. Further sample preparation and mRNA-Sequencing was
performed by the lab of Joachim Schultze (Life & Medical Sciences Institute,
University of Bonn), as well as the data analysis.
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6.2.2.8 Western Blot analysis
Cellular protein was purified by washing the cells once with PBS to remove extra-
cellular proteins, pelleted and resuspended at a concentration of 1·106 cells per 15
µl of Nonidet P-40 (NP-40) cell lysis buffer in the presence of protease inhibitors
(Protease Inhibitor Cocktail P8340 and phenylmethylsulfonyl fluoride (PMSF)
(both Sigma-Aldrich). Cells were lysed for 15 min on ice, followed by 5 min.
centrifugation at 2500g to remove intact nuclei and insoluble cellular debris. Both,
total cell lysates and supernatants were quantified using the QuantiT Protein
Assay Kit (Molecular Probes) to determine the exact protein concentration. Equal
amounts of protein were then denatured using sodium dodecyl sulfate (SDS) sam-
ple buffer at 95 ◦C for 7 min. and further subjected to SDS Page and Western blot.
Equal amounts of protein were loaded onto a 12-15% SDS gel prepared as
described in the Current Protocols in Immunology (Unit 8.9) and separated
by gel electrophoresis for 1.5 h at 80-100 V. PageRuler prestained protein
ladder (Thermo Scientific, Rockford, IL USA) was loaded as a protein standard.
Separated proteins were transferred onto a nitrocellulose membrane (Whatman)
using a tank transfer system (BIO-RAD) as described in the Current Protocols in
Immunology (Unit 8.10); transfer time was adjusted to 1.5 h at 80 V. Membranes
were blocked overnight in PBS supplemented with 0.5% Tween-20 and 5% milk.
After incubation with specific primary and secondary antibodies, membranes were
developed using enhanced chemiluminescence (ECL) Western blotting substrate
(PerkinElmer Inc., MA, USA) followed by exposure to Amersham Hyperfilm (GE
Healthcare). Specific bands were quantified relative to GAPDH as indicated in the
figure legends, using the free online tool ImageJ.
6.2.3 Statistics
Statistical analysis was performed using PRISM software (GraphPad software, La
Jolla, CA, USA). Unless stated otherwise all bar graphs represent mean± standard
error of mean (SEM) and significance was analyzed using Student’s t-test, with *:
p<0.01 to 0.05, **: p<0.001 to 0.01 and ***: p<0.001.
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